Node1	Edge_Type	Node2	Weight	Score	Paper_List	Original_Text
depression	disease	rumination	1	0	22964266	PMID:22964266; Original text:Results showed a significant reduction in depression, anxiety and rumination in the intervention group, as opposed to the control group.
anxiety	disease	depression	5	0	22964266|9934941|33381856|32090389|31947912	PMID:22964266; Original text:Results showed a significant reduction in depression, anxiety and rumination in the intervention group, as opposed to the control group.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:33381856; Original text:Self-reported anxiety was found to be significantly higher in youth with a lower Intelligence quotient, while depression was positively associated with Intelligence quotient.|PMID:32090389; Original text:Only the mindfulness-based stress reduction group demonstrated significant reductions in depression, and neither group significantly changed in anxiety.|PMID:31947912; Original text:A significant increase in risk was detected for autistic spectrum disorder (OR 1.53, 95% CI 1.24-1.88, p < 0.0001), attention deficit hyperactivity disorder (OR 1.39, 95% CI 1.18-1.63, p < 0.0001), depression (OR 2.17, 95% CI 2.17-11.15, p < 0.0001), anxiety (OR 6.03,
anxiety	disease	rumination	1	0	22964266	PMID:22964266; Original text:Results showed a significant reduction in depression, anxiety and rumination in the intervention group, as opposed to the control group.
adaptive	disease	adaptive disability	1	0	11893094	PMID:11893094; Original text:A significant discrepancy between intelligence and daily adaptive functioning, or adaptive disability (adaptive disability), has been previously found to be a associated with significant psychological morbidity in preschool children with disruptive behavior (disruptive behavior).
adaptive	disease	disruptive behavior	1	0	11893094	PMID:11893094; Original text:A significant discrepancy between intelligence and daily adaptive functioning, or adaptive disability (adaptive disability), has been previously found to be a associated with significant psychological morbidity in preschool children with disruptive behavior (disruptive behavior).
adaptive disability	disease	disruptive behavior	2	0	11893094|11893094	PMID:11893094; Original text:A significant discrepancy between intelligence and daily adaptive functioning, or adaptive disability (adaptive disability), has been previously found to be a associated with significant psychological morbidity in preschool children with disruptive behavior (disruptive behavior).|PMID:11893094; Original text:A significant contribution of adaptive disability to adverse outcomes in the disruptive behavior group remained on some measures even after controlling for initial severity of disruptive behavior.
adaptive disability	disease	cd	1	0	11893094	PMID:11893094; Original text:adaptive disability also contributed significantly to CD symptoms at follow-up after controlling for initial disruptive behavior severity and initial CD symptoms.
autistic	disease	epilepsy	3	0	34510916|18565495|18565495	PMID:34510916; Original text:A significantly increased prevalence of epilepsy was detected in the autistic adolescent group (11-17 years old), and a higher trend of prevalence of epilepsy was observed in the autistic pre-school group (⩽ 6 -years-old) than that of the autistic school-aged group (7-10 years-old).|PMID:18565495; Original text:There was a strong discrepancy in relative risk (relative risk) according to IQ, with more autistic patients with intellectual disability having epilepsy (relative risk = .555; 95% confidence interval [CI]: .42-.73; p < .001).|PMID:18565495; Original text:There was a strong discrepancy in relative risk according to sex, favoring comorbidity of epilepsy in autistic girls (relative risk = .549; 95% CI: .45-.66; p < .001).
autism	disease	catatonia	1	0	18427869	PMID:18427869; Original text:Catatonia should be assessed in people with autism when there is an obvious and marked deterioration in movement, vocalizations, pattern of activities, self-care, and practical skills.
autism spectrum disorders	disease	rheumatoid arthritis	1	0	28319657	PMID:28319657; Original text:Another case-control study showed a statistically significant 8-fold increase in autoimmune disorders, including rheumatoid arthritis, in mothers of offspring with autism spectrum disorders compared to controls.
autoimmune disorders	disease	rheumatoid arthritis	1	0	28319657	PMID:28319657; Original text:Another case-control study showed a statistically significant 8-fold increase in autoimmune disorders, including rheumatoid arthritis, in mothers of offspring with autism spectrum disorders compared to controls.
autism spectrum disorders	disease	autoimmune disorders	1	0	28319657	PMID:28319657; Original text:Another case-control study showed a statistically significant 8-fold increase in autoimmune disorders, including rheumatoid arthritis, in mothers of offspring with autism spectrum disorders compared to controls.
adhd	disease	anxiety	2	0	23455605|27043118	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.|PMID:27043118; Original text:In addition, memantine treatment was associated with significant improvement in ADHD and anxiety symptom severity.
adhd	disease	autism	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
adhd	disease	social	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
adhd	disease	emotional disorders	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
anxiety	disease	autism	6	0	23455605|22502839|9934941|23357440|27721995|11466160	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.|PMID:22502839; Original text:The Transcutaneous electrical acupoint stimulation group showed a significant improvement over the control in their emotional response, fear or anxiety, level/consistency of intellective relations and general impressions on the Childhood Autism Rating Scale (the Childhood Autism Rating Scale) as well as improvements in the sensory and related factors in the Autism Behavior Checklist (the Autism Behavior Checklist).|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:23357440; Original text:To examine the efficacy of a modular cognitive-behavioral therapy (a modular cognitive-behavioral therapy) protocol relative to treatment as usual (TAU) among children with high-functioning autism spectrum disorders (spectrum disorders) and clinically significant anxiety.|PMID:27721995; Original text:An intention-to-treat analysis showed significant overall gains for a wide range of symptoms in these children, including learning, memory, anxiety, attention span, motor skills, eating, sleeping, sensory processing, self-awareness, communication, social skills, and mood/autism behaviors.|PMID:11466160; Original text:After treatment, the patients showed significant improvement on the scores of the Yale--Brown Obsessive--Compulsive Scale -- Obsessions subscale and the Hamilton Anxiety Scale; Clinical Global Impressions -- Autism scores showed 3 of the patients much improved and 3 unchanged.
anxiety	disease	social	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
anxiety	disease	emotional disorders	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
autism	disease	social	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
autism	disease	emotional disorders	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
emotional disorders	disease	social	1	0	23455605	PMID:23455605; Original text:The risk associated with preterm birth is not a general one, but appears to be specific to symptoms and disorders associated with anxiety, inattention and social and communication problems, and manifest in a significantly higher prevalence of emotional disorders, ADHD and Autism.
hyperactivity	disease	irritability	18	0	26088658|26208985|19858761|24201232|9934941|19772883|23782127|18685284|22782459|22419332|32168067|30980177|32347624|19284641|32947424|23101743|25580916|22999292	PMID:26088658; Original text:Intent-to-treat analysis conducted on the 116 participants who completed a baseline assessment (therapeutic horseback riding n = 58; a barn activity control n = 58) revealed significant improvements in the therapeutic horseback riding group compared to the control on measures of irritability (primary outcome) (p = .02; effect size [ES] = 0.50) and hyperactivity (p = .01; ES = 0.53), beginning by week 5 of the intervention.|PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:19858761; Original text:Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, combined treatment showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04).|PMID:24201232; Original text:Among ABC-C subscales, Hyperactivity and Irritability showed significantly greater reduction in the amantadine group than the placebo group.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:19772883; Original text:The difference between the two protocols was significant as the group that received pentoxifylline had greater reduction in the Aberrant Behavior Checklist-Community subscale scores for Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance and Inappropriate Speech.|PMID:23782127; Original text:The ABC irritability/agitation subscale (subscale 1) was significantly improved from 8 weeks, and the hyperactivity/noncompliance subscale (subscale 4) was significantly improved in 12 weeks.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:22782459; Original text:Primary outcome measure was the change in irritability subscale of ABC-C. Significant time × treatment interaction was observed for Irritability (F (1.658, 63.0χ1) = 13.580, P < 0.001), Lethargy/Social Withdrawal (F (1.948, 74.03χ) = 16.811, P < 0.001), and Stereotypic Behavior (F(1.74χ, 66.198) = 1χ.104, P < 0.001), but not for Hyperactivity/Noncompliance (F (χ.564, 97.4χ4) = 1.469, P = 0.χ3χ), and Inappropriate Speech subscales (F (1.607, 61.075) = 0.173, P = 0.794).|PMID:22419332; Original text:In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms.|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).|PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).|PMID:23101743; Original text:The the behavior management treatment had shown a significant advantage for child behavioral noncompliance (p = .006, d = 0.34), irritability (p = .01, d = 0.48), and hyperactivity/noncompliance (p = .04, d = 0.55) with a lower medication dose.|PMID:25580916; Original text:Repeated-measures analysis showed significant effect for time × treatment interaction in irritability (P = 0.01) and hyperactivity/noncompliance (P = 0.02) subscales.|PMID:22999292; Original text:Difference between the two treatment arms was significant as the group that received memantine had greater reduction in Aberrant Behavior Checklist-Community subscale scores for irritability, stereotypic behaviour and hyperactivity.
autism	disease	sleep	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
autism	disease	parasomnias	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
autism	disease	sleep disorders	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
parasomnias	disease	sleep	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
sleep	disease	sleep disorders	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
parasomnias	disease	sleep disorders	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
autism	disease	sensory impairment	1	0	18826014	PMID:18826014; Original text:Sensory impairment is a common and significant feature of children on the autism spectrum.
anxiety	disease	autism spectrum disorder	1	0	32511015	PMID:32511015; Original text:Results indicated that clinician-rated anxiety severity and parent-rated externalizing behaviors and autism spectrum disorder severity significantly predicted pre-treatment accommodation.
neuro	disease	social	1	0	2487481	PMID:2487481; Original text:On the basis of the examinations of visual perception (retinal pathology, tunnel vision) perceptual processing (recognition of feelings, sex and age) and the disintegration of multimodal stimuli it can be presumed that social and emotional deficits are to be seen in connection with a deviant perceptive interpretation of the world and irregular processing on the basis of a neuro-biological handicap (the absence of a genetic determined reference-system for emotionally significant stimuli), which can have various causes (comp.
developmental disabilities	disease	disorders	2	0	23823984|24757919	PMID:23823984; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication and behavioral challenges.|PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.
autism spectrum	disease	developmental disabilities	2	0	23823984|24757919	PMID:23823984; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication and behavioral challenges.|PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.
autism spectrum	disease	disorders	2	0	23823984|24757919	PMID:23823984; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication and behavioral challenges.|PMID:24757919; Original text:Autism spectrum disorders (disorders) are a group of developmental disabilities that can cause significant social, communication, and behavioral challenges for children and families.
autistic	disease	necrosis	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease	tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease	tumor	1	0	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
neurocognitive decline	disease	neuronopathic mucopolysaccharidoses ii	1	0	30442188	PMID:30442188; Original text:Patients with neuronopathic Mucopolysaccharidoses II have a plateau of cognitive and adaptive development on average by 4 to 4.5 years of age, although there is significant variability, followed by progressive neurocognitive decline.
alzheimer's disease	disease	parkinson's disease	1	0	30577116	PMID:30577116; Original text:We found significant association between PM2.5 exposure and stroke, dementia, Alzheimer's disease, disorder, Parkinson's disease.
parkinson's disease	disease	stroke	1	0	30577116	PMID:30577116; Original text:We found significant association between PM2.5 exposure and stroke, dementia, Alzheimer's disease, disorder, Parkinson's disease.
dementia	disease	parkinson's disease	1	0	30577116	PMID:30577116; Original text:We found significant association between PM2.5 exposure and stroke, dementia, Alzheimer's disease, disorder, Parkinson's disease.
alzheimer's disease	disease	stroke	1	0	30577116	PMID:30577116; Original text:We found significant association between PM2.5 exposure and stroke, dementia, Alzheimer's disease, disorder, Parkinson's disease.
alzheimer's disease	disease	dementia	2	0	30577116|23471985	PMID:30577116; Original text:We found significant association between PM2.5 exposure and stroke, dementia, Alzheimer's disease, disorder, Parkinson's disease.|PMID:23471985; Original text:Older people who carried the connectivity variant had significantly milder clinical dementia scores and lower risk of Alzheimer's disease.
dementia	disease	stroke	1	0	30577116	PMID:30577116; Original text:We found significant association between PM2.5 exposure and stroke, dementia, Alzheimer's disease, disorder, Parkinson's disease.
endocytosis	disease	viral myocarditis	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
attention-deficit/hyperactivity disorder	disease	viral myocarditis	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
attention-deficit/hyperactivity disorder	disease	endocytosis	1	0	31685286	PMID:31685286; Original text:Pathway enrichment analysis of the genes identified by Tissue specific transcriptome-wide association study detected 3 pathways for Attention-deficit/hyperactivity disorder, including Other glycan degradation (P value=0.021), Viral myocarditis (P value=0.034) and Endocytosis (P value=0.041).
obsessive-compulsive disorder	disease	psychiatric disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
personality disorders	disease	psychiatric disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
primary	disease	psychiatric disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
major depressive disorder	disease	psychiatric disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
psychiatric disorders	disease	schizophrenia	3	0	32129844|27748930|21863344	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.|PMID:21863344; Original text:Empathy, for instance, is a rather elaborated human ability, and several recent studies point to significant impairments in patients suffering from psychiatric disorders, such as schizophrenia or autism.
bipolar disorder	disease	psychiatric disorders	2	0	32129844|27748930	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
bvftd	disease	psychiatric disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	psychiatric disorders	2	0	32129844|27748930	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
psychiatric disorders	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
obsessive-compulsive disorder	disease	personality disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
obsessive-compulsive disorder	disease	primary	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
major depressive disorder	disease	obsessive-compulsive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
obsessive-compulsive disorder	disease	schizophrenia	2	0	32129844|32503201	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:32503201; Original text:(Obsessive-Compulsive Disorder), one on Schizophrenia (Schizophrenia) and one on Eating Disorders (Eating Disorders).
bipolar disorder	disease	obsessive-compulsive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bvftd	disease	obsessive-compulsive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	obsessive-compulsive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
obsessive-compulsive disorder	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
personality disorders	disease	primary	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
major depressive disorder	disease	personality disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
personality disorders	disease	schizophrenia	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bipolar disorder	disease	personality disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bvftd	disease	personality disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	personality disorders	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
personality disorders	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
major depressive disorder	disease	primary	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
primary	disease	schizophrenia	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bipolar disorder	disease	primary	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bvftd	disease	primary	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	primary	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
primary	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
major depressive disorder	disease	schizophrenia	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bipolar disorder	disease	major depressive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bvftd	disease	major depressive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	major depressive disorder	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
major depressive disorder	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bipolar disorder	disease	schizophrenia	4	0	32129844|27748930|29045744|31780770	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.|PMID:29045744; Original text:The predictive risk of each isolated developmental marker is low, but a significant percentage of subjects with schizophrenia and a minority of adults with bipolar disorder showed signs of premorbid abnormalities in childhood.|PMID:31780770; Original text:In a direct comparison between schizophrenia and bipolar disorder, there were no significant differences.
bvftd	disease	schizophrenia	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	schizophrenia	3	0	32129844|27748930|28152400	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.|PMID:28152400; Original text:There is increasing evidence to suggest both a symptomatic overlap and a clinically significant degree of co-occurrence between Autism Spectrum Disorders (Autism Spectrum Disorders) and psychotic disorders such as schizophrenia but the nature of such relationships remain unclear.
schizophrenia	disease	symptomatic	2	0	32129844|28152400	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:28152400; Original text:There is increasing evidence to suggest both a symptomatic overlap and a clinically significant degree of co-occurrence between Autism Spectrum Disorders (Autism Spectrum Disorders) and psychotic disorders such as schizophrenia but the nature of such relationships remain unclear.
bipolar disorder	disease	bvftd	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	bipolar disorder	2	0	32129844|27748930	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
bipolar disorder	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	bvftd	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
bvftd	disease	symptomatic	1	0	32129844	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.
autism spectrum disorders	disease	symptomatic	2	0	32129844|28152400	PMID:32129844; Original text:BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders.|PMID:28152400; Original text:There is increasing evidence to suggest both a symptomatic overlap and a clinically significant degree of co-occurrence between Autism Spectrum Disorders (Autism Spectrum Disorders) and psychotic disorders such as schizophrenia but the nature of such relationships remain unclear.
autism spectrum disorder	disease	impairment in social skills	1	0	23055002	PMID:23055002; Original text:Children with an autism spectrum disorder have significant impairment in social skills.
asd	disease	infections	1	0	25302490	PMID:25302490; Original text:No adverse events of significance were observed in ASD children treated with fetal stem cells, including no transmitted infections or immunological complications.
autistic	disease	macrocephaly	1	0	26456415	PMID:26456415; Original text:Head circumference was significantly larger in autistic compared to control individuals, with 822/5225 (15.7%) autistic individuals displaying macrocephaly.
depression	disease	irritability	3	0	9672054|15529462|9934941	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
irritability	disease	nervousness	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
irritability	disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
autism	disease	irritability	4	0	9672054|9934941|31725473|32168067	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:31725473; Original text:Results from the general linear model repeated measures analysis demonstrated significant time-treatment interaction on irritability subscale (F1.55 = 3.45; P = 0.048) and Childhood Autism Rating Scale (F1.41 = 4.08; P = 0.034) scores.|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
aggression	disease	irritability	6	0	9672054|9934941|15746480|19519261|22549762|20010551	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:15746480; Original text:Subjects' the Overt Aggression Scale aggression scores showed significant correlation with the already validated retrospectively rated Aberrant Behavior Checklist Community Scale irritability subscale.|PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.|PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.|PMID:20010551; Original text:Irritability/aggression is a significant comorbid symptom in this population, which greatly impacts burden of care.
anxiety or	disease	irritability	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
depression	disease	nervousness	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
depression	disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
autism	disease	depression	2	0	9672054|9934941	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
aggression	disease	depression	2	0	9672054|9934941	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anxiety or	disease	depression	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
nervousness	disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
autism	disease	nervousness	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
aggression	disease	nervousness	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
anxiety or	disease	nervousness	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
autism	disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
aggression	disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
anxiety or	disease	repetitive behavior	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
aggression	disease	autism	3	0	9672054|18439113|9934941	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:18439113; Original text:Aggression and self-injury may be associated symptoms of autism and can result in significant harm to those affected as well as marked distress for their families.|PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anxiety or	disease	autism	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
aggression	disease	anxiety or	1	0	9672054	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).
impairments	disease	learning impaired	1	0	7002017	PMID:7002017; Original text:The effects of preschool impairments in language development on subsequent school achievement are significant: 60% of these children are in special classes for the learning impaired at 9 years of age.
asd	disease	autism	4	0	29498298|30617550|31665947|25941080	PMID:29498298; Original text:Some of these liabilities are not necessarily specific to ASD-those that are non-specific could account for a significant share of the 'missing heritability' of autism, would (by definition) contribute to pleiotropy, and relate to so-called 'co-morbidities', which are inappropriately named if they actually contribute to (or exacerbate) the severity of autism itself.|PMID:30617550; Original text:Level 1 screening tools for ASD showed consistent statistically significant results and therefore are adequate to detect autism at 14-36 months.|PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.|PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
neuropsychiatric disorders	disease	tuberous sclerosis	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
mood disorders	disease	tuberous sclerosis	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
autism spectrum disorder	disease	tuberous sclerosis	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
intellectual disability	disease	tuberous sclerosis	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
mood disorders	disease	neuropsychiatric disorders	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
autism spectrum disorder	disease	neuropsychiatric disorders	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
intellectual disability	disease	neuropsychiatric disorders	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
autism spectrum disorder	disease	mood disorders	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
intellectual disability	disease	mood disorders	1	0	32222129	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.
autism spectrum disorder	disease	intellectual disability	4	0	32222129|28929285|24231171|33434711	PMID:32222129; Original text:Tuberous sclerosis complex associated neuropsychiatric disorders (neuropsychiatric disorders), including intellectual disability, mood disorders, and autism spectrum disorder, represent significant challenges but remain underdiagnosed and undertreated.|PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.|PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
autism	disease	spectrum disorders	2	0	22228009|23357440	PMID:22228009; Original text:There now exist multiple lines of evidence pointing to a significant genetic component underlying the aetiology of autism spectrum disorders (spectrum disorders).|PMID:23357440; Original text:To examine the efficacy of a modular cognitive-behavioral therapy (a modular cognitive-behavioral therapy) protocol relative to treatment as usual (TAU) among children with high-functioning autism spectrum disorders (spectrum disorders) and clinically significant anxiety.
epilepsy and	disease	sleep disorders	1	0	21293268	PMID:21293268; Original text:As epilepsy and sleep disorders can be treated and may contribute significantly to behavioral and cognitive abnormalities in autism spectrum disorders, their identification is of high clinical relevance.
autism spectrum disorders	disease	epilepsy and	1	0	21293268	PMID:21293268; Original text:As epilepsy and sleep disorders can be treated and may contribute significantly to behavioral and cognitive abnormalities in autism spectrum disorders, their identification is of high clinical relevance.
behavioral and cognitive abnormalities	disease	epilepsy and	1	0	21293268	PMID:21293268; Original text:As epilepsy and sleep disorders can be treated and may contribute significantly to behavioral and cognitive abnormalities in autism spectrum disorders, their identification is of high clinical relevance.
autism spectrum disorders	disease	sleep disorders	1	0	21293268	PMID:21293268; Original text:As epilepsy and sleep disorders can be treated and may contribute significantly to behavioral and cognitive abnormalities in autism spectrum disorders, their identification is of high clinical relevance.
behavioral and cognitive abnormalities	disease	sleep disorders	1	0	21293268	PMID:21293268; Original text:As epilepsy and sleep disorders can be treated and may contribute significantly to behavioral and cognitive abnormalities in autism spectrum disorders, their identification is of high clinical relevance.
autism spectrum disorders	disease	behavioral and cognitive abnormalities	1	0	21293268	PMID:21293268; Original text:As epilepsy and sleep disorders can be treated and may contribute significantly to behavioral and cognitive abnormalities in autism spectrum disorders, their identification is of high clinical relevance.
autism	disease	spectrum disorder	1	0	33573238	PMID:33573238; Original text:There has been a growing interest in the gastrointestinal system and its significance for autism spectrum disorder (spectrum disorder), including the significance of adopting a gluten-free and casein-free (GFCF) diet.
asperger syndrome	disease	attention deficit hyperactivity disorder	4	0	31965841|31965841|25760553|25760553	PMID:31965841; Original text:attention deficit hyperactivity disorder or Asperger syndrome was diagnosed at the age of 13 years in 17.1% children in the placebo and none in the probiotic group (P=0.008).|PMID:31965841; Original text:This study found significant differences in species composition and number of cells belonging to the genus Bifidobacterium between healthy children and children who later developed attention deficit hyperactivity disorder or Asperger syndrome at different time points.|PMID:25760553; Original text:At the age of 13 y, attention deficit hyperactivity disorder or Asperger syndrome was diagnosed in 6/35 (17.1%) children in the placebo and none in the probiotic group (P = 0.008).|PMID:25760553; Original text:The diagnoses of attention deficit hyperactivity disorder (attention deficit hyperactivity disorder) and Asperger syndrome (Asperger syndrome) by a child neurologist or psychiatrist were based on ICD-10 diagnostic criteria.
clumsiness	disease	hypersensitivity to sound	1	0	30287864	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.
autism	disease	developmental disorders	1	0	16083327	PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.
asperger	disease	autism	1	0	16083327	PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.
asperger	disease	developmental disorders	1	0	16083327	PMID:16083327; Original text:Autism, Asperger and other pervasive developmental disorders (other pervasive developmental disorders) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour.
drooling	disease	fatigue	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
drowsiness	disease	fatigue	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
dizziness	disease	fatigue	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
fatigue	disease	increased appetite	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
drooling	disease	drowsiness	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
dizziness	disease	drooling	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
drooling	disease	increased appetite	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
dizziness	disease	drowsiness	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
drowsiness	disease	increased appetite	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
dizziness	disease	increased appetite	1	0	12151468	PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).
autism	disease	autistic disorder	3	0	22987897|32006372|16078860	PMID:22987897; Original text:We conclude that a 20-week parent education programme including skills training for parents of young children with autistic disorder provides significant improvements in child adaptive behaviour and symptoms of autism for low-functioning children.|PMID:32006372; Original text:This paper will discuss recent literature on the significance of metabolic aspects in autistic disorder and highlight the influence of nutrition intervention on the symptoms of autism.|PMID:16078860; Original text:Although there has been a significant increase in autism genetics research recently, validated susceptibility genes for the most common, sporadic forms of autistic disorder, as well as familial autism, have yet to be identified.
autism	disease	maladaptive	1	0	24439092	PMID:24439092; Original text:These findings suggest that NeuroModulation Technique is a promising intervention for autism that has the potential to produce a significant reduction in maladaptive behaviors and a significant increase in adaptive behaviors within a relatively short period of time.
autism	disease	autistic	6	0	24375082|3513570|22688012|28217829|17531541|11408327	PMID:24375082; Original text:camel milk administered for 2 wk significantly improved clinical measurements of autism severity and decreased serum level of activation-regulated chemokine in autistic children, but subsequent studies are recommended.|PMID:3513570; Original text:With an overall 7.7% frequency of fra(X) among autistic males and an estimated 12.3% of autism among fra(X) males, we conclude there is likely to be a significant association of fra(X) with autism.|PMID:22688012; Original text:The majority of the data are based on molecular, cytogenetic, linkage and association studies of autistic subjects, but newer methods, including whole-exome sequencing, are also beginning to make significant contributions to our understanding of autism.|PMID:28217829; Original text:In terms of prevention, a recent small study showed vitamin D supplementation during pregnancy (5000 IU/day) and during infancy and early childhood (1000 IU/day) significantly reduced the expected incidence of autism in mothers who already had one autistic child from 20% to 5%.|PMID:17531541; Original text:One final point is the initial overgrowth of white matter in the first 2 years of life in autistic children, followed later by arrested growth, resulting in aberrant connectivity; myelination of white matter will likely be significant in the etiology of autism.|PMID:11408327; Original text:The cross-sectional area of the AD was significantly smaller than normal in autism, the largest deviation from normal size (-13.5%) being found in autistic children aged 29 months to 4 years.
aggression	disease	pervasive developmental disorders	1	0	16190799	PMID:16190799; Original text:In this prospective double-blind, placebo-controlled study, 30 subjects (20 boys, 10 girls) 6-20 years of age with pervasive developmental disorders and significant aggression were randomized and received treatment with valproate (VPA) or placebo (PBO) for 8 weeks as outpatients.
autism	disease	physical anomalies	2	0	18626481|18626481	PMID:18626481; Original text:Using the cumulative data from seven studies on minor physical anomalies in autism, this meta-analysis seeks to examine whether the aggregate data provide evidence of a large mean effect size and statistical significance for minor physical anomalies in autism.|PMID:18626481; Original text:The current results from seven studies suggested a significant association of minor physical anomalies in autism with a robust pooled effect size (d=0.84), and thereby provide the strongest evidence to date about the close association between minor physical anomalies and autism.
autism	disease	vascular pathology	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
autism	disease	cerebral hypoperfusion	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
cerebral hypoperfusion	disease	vascular pathology	1	0	29694338	PMID:29694338; Original text:Moreover, correlations between symptom scores and hypoperfusion in the brains of individuals diagnosed with an disorder were found indicating that the greater the autism symptom pathology, the more significant the cerebral hypoperfusion or vascular pathology in the brain.
autism	disease	developmental disabilities	1	0	17923388	PMID:17923388; Original text:IQ scores increased significantly more in the autism group than in the developmental disabilities group.
autism	disease	cognitive increments	1	0	17923388	PMID:17923388; Original text:Improvement of social-communicative behaviors and the intensive intervention are related to significant cognitive increments in autism.
neurodevelopmental disorders	disease	neuroimaging	1	0	29608989	PMID:29608989; Original text:Significant advances have been made already, and future decades will continue to see innovative progress in neuroimaging research endeavors of neurodevelopmental disorders.
acrophobia	disease	obsessive-compulsive disorder	1	0	31166547	PMID:31166547; Original text:In the obsessive-compulsive disorder and acrophobia trials, rTMS significantly reduced symptoms compared to placebo.
asperger's syndrome	disease	autism	2	0	12818906|2047334	PMID:12818906; Original text:Discriminant functions analysis shows pathological demand avoidance syndrome to be significantly different on many counts from classic autism and Asperger's syndrome, both separately and together, including an equal sex ratio (150 cases).|PMID:2047334; Original text:Although some differences in etiology between autism and Asperger's syndrome have been identified, these are of uncertain clinical significance.
inflammation	disease	vascular disease	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
inflammation	disease	traumatic injury	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
degenerative disease	disease	inflammation	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
traumatic injury	disease	vascular disease	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
degenerative disease	disease	vascular disease	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
degenerative disease	disease	traumatic injury	1	0	33942547	PMID:33942547; Original text:Oxidative stress (Oxidative stress) is one of the most significant propagators of systemic damage with implications for widespread pathologies such as vascular disease, accelerated aging, degenerative disease, inflammation, and traumatic injury.
autism	disease	epileptiform activity	1	0	25847431	PMID:25847431; Original text:The clinical significance of epileptiform activity in patients with autism is controversial.
asd	disease	asds	1	0	26448791	PMID:26448791; Original text:A an existing computer decision support system module to improve primary care management of ASD in pediatric practice led to significant improvements in physician-reported use of validated screening tools to screen for ASDs.
asd	disease	psychosis	1	0	33218931	PMID:33218931; Original text:The 22q11.2 microdeletion syndrome (The 22q11.2 microdeletion syndrome) is caused by a recurrent genetic mutation that carries significantly increased risk for developing psychosis and/or ASD.
autism spectrum disorders	disease	impairments in gaze fixation to the eyes	1	0	24988218	PMID:24988218; Original text:The results of the meta-analyses indicate that autism spectrum disorders patients have significant impairments in gaze fixation to the eyes.
autism spectrum disorder	disease	schizophrenia	2	0	28929285|33434711	PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
autism spectrum disorder	disease	genomic disorders	1	0	28929285	PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.
intellectual disability	disease	schizophrenia	3	0	28929285|33434711|24123946	PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.|PMID:24123946; Original text:The del15q11.2 was found to be significantly associated with intellectual disability, schizophrenia, epilepsy, and disorder.
genomic disorders	disease	intellectual disability	1	0	28929285	PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.
genomic disorders	disease	schizophrenia	1	0	28929285	PMID:28929285; Original text:Although individually rare, genomic disorders collectively account for a significant minority of intellectual disability, autism spectrum disorder, and schizophrenia.
fragile x syndrome	disease	visuospatial impairments	1	0	30231625	PMID:30231625; Original text:Children with Fragile X syndrome also exhibit significant visuospatial impairments.
autism spectrum disorders	disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
bipolar depression	disease	mdd	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
autism spectrum disorders	disease	bipolar depression	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
anxiety disorder	disease	olanzapine	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
anxiety disorder	disease	dementia	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
anxiety disorder	disease	obsessive-compulsive disorder	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
dementia	disease	olanzapine	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
obsessive-compulsive disorder	disease	olanzapine	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
dementia	disease	obsessive-compulsive disorder	1	0	22784311	PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
sah	disease	sam	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
autism	disease	fever	1	0	33720503	PMID:33720503; Original text:Analyses demonstrated a statistically significant association of maternal infection/fever with autism in offspring (OR = 1.32; 95% CI = 1.20-1.46).
fever	disease	infection	1	0	33720503	PMID:33720503; Original text:Analyses demonstrated a statistically significant association of maternal infection/fever with autism in offspring (OR = 1.32; 95% CI = 1.20-1.46).
autism	disease	infection	2	0	33720503|33720503	PMID:33720503; Original text:Analyses demonstrated a statistically significant association of maternal infection/fever with autism in offspring (OR = 1.32; 95% CI = 1.20-1.46).|PMID:33720503; Original text:This study is a meta-analysis of the association of maternal infection during pregnancy and subsequent autism in offspring.
depression	disease	psychiatric disorders	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
depression	disease	suicidality	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
cancer	disease	depression	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
depression	disease	schizophrenia	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
bipolar disorder	disease	depression	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
autism spectrum disorders	disease	depression	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
psychiatric disorders	disease	suicidality	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
cancer	disease	psychiatric disorders	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
cancer	disease	suicidality	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
schizophrenia	disease	suicidality	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
bipolar disorder	disease	suicidality	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
autism spectrum disorders	disease	suicidality	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
cancer	disease	schizophrenia	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
bipolar disorder	disease	cancer	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
autism spectrum disorders	disease	cancer	1	0	27748930	PMID:27748930; Original text:Recent evidence has indicated that microRNAs (miRNAs or miRs), a large group of small non‑coding oligonoucleotides, may play a significant role in the development of cancer and major psychiatric disorders, such as Schizophrenia, bipolar disorder, autism spectrum disorders, suicidality and depression, through their interference with the expression of multiple genes.
inherited	disease	neurologically	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
neurological deterioration	disease	neurologically	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
metabolic diseases	disease	neurologically	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
inherited	disease	neurological deterioration	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
inherited	disease	metabolic diseases	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
metabolic diseases	disease	neurological deterioration	1	0	28985203	PMID:28985203; Original text:hematopoietic stem cell transplantation is currently an established therapy for certain neurologically devastating inherited metabolic diseases, in which engrafting donor cells provide lifelong enzyme replacement that prevents neurological deterioration and significantly extends the lives of affected children.
apraxia of speech	disease	autism	1	0	22450249	PMID:22450249; Original text:Autism, childhood apraxia of speech and central auditory processing disorder are associated with significant disability.
auditory processing disorder	disease	autism	1	0	22450249	PMID:22450249; Original text:Autism, childhood apraxia of speech and central auditory processing disorder are associated with significant disability.
apraxia of speech	disease	auditory processing disorder	1	0	22450249	PMID:22450249; Original text:Autism, childhood apraxia of speech and central auditory processing disorder are associated with significant disability.
autism	disease	autism spectrum disorder	3	0	26577969|28934215|23782128	PMID:26577969; Original text:Significant differences were detected on Autism Spectrum Disorder (Autism Spectrum Disorder) by Childhood Autism Rating Scale, Social Responsiveness Scale and Autism Treatment Evaluation Checklist scales, following 2 weeks of camel milk consumption, but not in the placebo group.|PMID:28934215; Original text:No changes were observed for meeting the autism spectrum disorder criteria over time (risk difference [RD] = -0.01, 95% CI -0.03 to 0.01), but a significant change for meeting autism criteria over time (RD = -0.18, 95% CI -0.29 to -0.07).|PMID:23782128; Original text:(DSM-IV-TR) criteria for an autism spectrum disorder (disorder) on the Autism Diagnostic Interview-Revised (-Revised) and the Autism Diagnostic Observation Schedule (the Autism Diagnostic Observation Schedule), and had significant symptoms of attention-deficit/hyperactivity disorder (attention-deficit/hyperactivity disorder).
autistic traits	disease	behavioral addiction	1	0	34325098	PMID:34325098; Original text:Results included 27 studies that found a positive correlation (15 of significance, 12 of unknown significance) between a behavioral addiction and either disorder or Autistic traits, 1 found a significant negative correlation, 3 did not find a correlation.
asd	disease	memory	1	0	28102493	PMID:28102493; Original text:A significant working memory impairment (Cohen's d = -0.61) was identified in the individuals with ASD, however, this impairment was not associated with age.
anhedonia	disease	irritability	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
irritability	disease	somatic complaints	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
anhedonia	disease	depression	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
depression	disease	somatic complaints	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
anhedonia	disease	somatic complaints	1	0	15529462	PMID:15529462; Original text:Clinicians need to inquire about not only classic symptoms of depression such as anhedonia but also less obvious symptoms such as unprovoked irritability, unsubstantiated complaints of lack of love from family members, somatic complaints, and problems with concentration and poor school performance.
catatonic	disease	declines in motor movements	1	0	16697293	PMID:16697293; Original text:Clinicians might also need to assess for signs of significant declines in motor movements, as this appears to be a useful diagnostic indicator of catatonic-like symptoms.
adhd	disease	disorder(asd	1	0	32845025	PMID:32845025; Original text:Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD).
autism spectrum	disease	disorder(asd	1	0	32845025	PMID:32845025; Original text:Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD).
attention-deficit/hyperactivity disorder	disease	disorder(asd	1	0	32845025	PMID:32845025; Original text:Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD).
adhd	disease	autism spectrum	1	0	32845025	PMID:32845025; Original text:Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD).
adhd	disease	attention-deficit/hyperactivity disorder	1	0	32845025	PMID:32845025; Original text:Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD).
attention-deficit/hyperactivity disorder	disease	autism spectrum	1	0	32845025	PMID:32845025; Original text:Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD).
autism	disease	language delay	1	0	25346345	PMID:25346345; Original text:Fifty-three children with autism and significant language delay between 2 and 6 years old were randomized to Pivotal Response TreatmentG (N = 27) or psychoeducation group (PEG;
autistic	disease	seizure	1	0	7854533	PMID:7854533; Original text:Measures of these structures in autistic patients and normal healthy volunteers differed nonsignificantly, by less than 1.4%, regardless of whether or not the autistic patients were retarded or had a history of seizure episodes.
bipolar disorder	disease	suicidal thoughts	1	0	26276916	PMID:26276916; Original text:Previous studies have clearly indicated that in the group of patients with an early onset of the bipolar disorder the occurrence of suicidal thoughts and intentions were significantly increased.
autism spectrum disorder	disease	obesity	1	0	34520698	PMID:34520698; Original text:Obesity represents a significant threat to quality of life and overall health for typically and a typically developing children with those diagnosed with Autism Spectrum Disorder (Autism Spectrum Disorder) having obesity prevalence at least as high as their typically developing counterparts.
asd	disease	depressive disorder	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
bipolar disorder	disease	depressive disorder	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
depressive disorder	disease	obsessive compulsive disorder	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
asd	disease	bipolar disorder	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
asd	disease	obsessive compulsive disorder	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
bipolar disorder	disease	obsessive compulsive disorder	1	0	33456050	PMID:33456050; Original text:The standardized mean differences were significantly correlated between SCZ and bipolar disorder, obsessive compulsive disorder, major depressive disorder, and ASD.
asperger syndrome	disease	autism	2	0	20162344|8986845	PMID:20162344; Original text:Across 27 students age 11-14 with a high functioning autism/Asperger Syndrome diagnosis, results indicated significant improvement on parent reports of social skills and executive functioning.|PMID:8986845; Original text:13 (76%) of the Asperger syndrome patients were rated as pedantic compared to 4 (31%) of the high-functioning autism group (chi 2 = 6.3; p = .01).
attention	disease	depressive	1	0	23503544	PMID:23503544; Original text:Significant, but modest, decreases in the severity of depressive symptoms (CDRS before vs after scores: 65.5 ± 10.8 vs 58.3 ± 8.2; paired t test, 3.1; df, 10; P =0.01) and attention-deficit/hyperactivity disorder symptoms (Attention Deficit/Hyperactivity Disorder Rating Scale before vs after: 36.4 ± 5 vs 32.8 ± 5; paired-t test, 2.94; df, 10; P = 0.015) were obtained after reboxetine treatment.
attention-deficit/hyperactivity disorder	disease	depression	1	0	23503544	PMID:23503544; Original text:A significant positive correlation was found between the changes in the total scores of the depression and the attention-deficit/hyperactivity disorder severity (Spearman correlation r = 0.65
n	disease	negative	1	0	16401163	PMID:16401163; Original text:We found a statistically significant improvement from baseline for last-observation-carried-forward (last-observation-carried-forward) analyses as well as for analyses of 12-week completers (N = 9) in our primary outcome measure, Negative Symptoms scores (F = 13.41, p < .0001 for 12-week completers; F = 9.64, p < .0001 for last-observation-carried-forward).
language delay	disease	language or cognitive delay	1	0	21406158	"PMID:21406158; Original text:One approach to resolve this question has been to adopt the criterion of absence of clinically significant language or cognitive delay--essentially, the ""absence of language delay."""
autism spectrum disorder	disease	tooth decay	1	0	31931609	PMID:31931609; Original text:After a systematic search in the literature, we found that the salivary pH of individuals diagnosed with Autism Spectrum Disorder was significantly lower, but the results were not clinically significant that can increase their risks to tooth decay.
epilepsy	disease	sleep problems	1	0	20087181	PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.
epilepsy	disease	gastrointestinal conditions	1	0	20087181	PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.
gastrointestinal conditions	disease	sleep problems	1	0	20087181	PMID:20087181; Original text:There continues to be disagreement regarding the exact prevalence and etiological significance of gastrointestinal conditions, epilepsy and other abnormal electroencephalographic findings, and sleep problems.
autism spectrum disorders	disease	repetitive behaviours	1	0	15132762	PMID:15132762; Original text:Patients with autism spectrum disorders showed a significant increase in repetitive behaviours at end-point following oral m-CPP in comparison to placebo.
autism spectrum disorders	disease	repetitive behaviors	2	0	12496956|28577609	PMID:12496956; Original text:Patients with autism spectrum disorders showed a significant reduction in repetitive behaviors following oxytocin infusion in comparison to placebo infusion.|PMID:28577609; Original text:Autism spectrum disorders (disorders) are neurodevelopmental disorders whose core features of impaired social communication and atypical repetitive behaviors and/or restrictions in range of interests emerge in toddlerhood and carry significant implications at successive stages of development.
autism	disease	medical disorders	1	0	1950971	PMID:1950971; Original text:No single biomedical etiology has been found, but a significant number of medical disorders occur in association with autism.
communication disorders	disease	intellectual disabilities	1	0	27318612	PMID:27318612; Original text:The purpose of this study was to teach letter-sound correspondence to small groups of students with significant intellectual disabilities and comorbid communication disorders using the ALL (Accessible Literacy Learning) curriculum.
anxiety	disease	difficulty falling asleep	1	0	16379507	"PMID:16379507; Original text:""Difficulty falling asleep"" and anxiety actually favored the risperidone condition at statistically significant levels."
aggression	disease	self-injury	2	0	18439113|22549762	PMID:18439113; Original text:Aggression and self-injury may be associated symptoms of autism and can result in significant harm to those affected as well as marked distress for their families.|PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
autism	disease	self-injury	1	0	18439113	PMID:18439113; Original text:Aggression and self-injury may be associated symptoms of autism and can result in significant harm to those affected as well as marked distress for their families.
depressive	disease	depressive symptoms	1	0	24217336	PMID:24217336; Original text:For depressive symptoms, the risk reduction in clinically significant symptoms did not reach statistical significance (5.7% vs 22.4%; aRR, 0.33; 95% CI, 0.10 to 1.08); however, the reduction in mean depressive symptoms was statistically significant (Quick Inventory of Depressive Symptomatology score, 4.6 with problem-solving education vs 6.9 with usual care; adjusted mean difference, -1.67; 95% CI, -3.17 to -0.18).
febrile seizure	disease	per	1	0	25382662	PMID:25382662; Original text:On a per microgram of organic an organic mercury basis, cases diagnosed with a pervasive developmental disorder in comparison to controls were at significantly greater odds (odds ratio = 1.0197, p < 0.0001) of receiving increasing organic an organic mercury exposure within the first 15 months of life, whereas cases diagnosed febrile seizure were no more likely than controls (odds ratio = 0.999, p > 0.20) to have received increasing organic an organic mercury exposure within the first 15 months of life.
per	disease	pervasive developmental disorder	1	0	25382662	PMID:25382662; Original text:On a per microgram of organic an organic mercury basis, cases diagnosed with a pervasive developmental disorder in comparison to controls were at significantly greater odds (odds ratio = 1.0197, p < 0.0001) of receiving increasing organic an organic mercury exposure within the first 15 months of life, whereas cases diagnosed febrile seizure were no more likely than controls (odds ratio = 0.999, p > 0.20) to have received increasing organic an organic mercury exposure within the first 15 months of life.
febrile seizure	disease	pervasive developmental disorder	1	0	25382662	PMID:25382662; Original text:On a per microgram of organic an organic mercury basis, cases diagnosed with a pervasive developmental disorder in comparison to controls were at significantly greater odds (odds ratio = 1.0197, p < 0.0001) of receiving increasing organic an organic mercury exposure within the first 15 months of life, whereas cases diagnosed febrile seizure were no more likely than controls (odds ratio = 0.999, p > 0.20) to have received increasing organic an organic mercury exposure within the first 15 months of life.
irritability	disease	stereotypic behavior	2	0	26208985|30980177	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
irritability	disease	social withdrawal	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
irritability	disease	lethargy	6	0	26208985|19772883|18685284|32168067|30980177|26802979	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:19772883; Original text:The difference between the two protocols was significant as the group that received pentoxifylline had greater reduction in the Aberrant Behavior Checklist-Community subscale scores for Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance and Inappropriate Speech.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:26802979; Original text:Significant (P<0.01) interactions between treatment and baseline severity were observed for parent ABC ratings of irritability and lethargy only.
inappropriate speech	disease	irritability	4	0	26208985|18685284|22419332|30980177	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:22419332; Original text:In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
social withdrawal	disease	stereotypic behavior	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
lethargy	disease	stereotypic behavior	2	0	26208985|30980177	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
inappropriate speech	disease	stereotypic behavior	2	0	26208985|30980177	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
hyperactivity	disease	stereotypic behavior	2	0	26208985|30980177	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
lethargy	disease	social withdrawal	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
inappropriate speech	disease	social withdrawal	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
hyperactivity	disease	social withdrawal	1	0	26208985	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.
inappropriate speech	disease	lethargy	4	0	26208985|18685284|30980177|29027815	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:29027815; Original text:No significant improvements were obtained on the lethargy/social withdrawal, stereotypic behavior, and inappropriate speech subscale scores.
hyperactivity	disease	lethargy	5	0	26208985|19772883|18685284|32168067|30980177	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:19772883; Original text:The difference between the two protocols was significant as the group that received pentoxifylline had greater reduction in the Aberrant Behavior Checklist-Community subscale scores for Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance and Inappropriate Speech.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).
hyperactivity	disease	inappropriate speech	6	0	26208985|18685284|11392343|22419332|30980177|33029705	PMID:26208985; Original text:Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group.|PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).|PMID:11392343; Original text:However, in the amantadine-treated group there were statistically significant improvements in absolute changes in clinician-rated ABC-CVs for hyperactivity (amantadine -6.4 versus placebo -2.1; p = .046) and inappropriate speech (-1.9 versus 0.4; p = .008).|PMID:22419332; Original text:In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms.|PMID:30980177; Original text:Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004).|PMID:33029705; Original text:The repeated measures analysis showed significant effect for time × treatment interaction on inappropriate speech (F = 3.51; df = 1.61; P = 0.044), stereotypic behavior (F = 4.02; df = 1.37; P = 0.036), and hyperactivity/noncompliance (F = 6.79; df = 1.66; P = 0.003) subscale scores.
disrupted brain connectivity	disease	molecular lesions	1	0	27282107	PMID:27282107; Original text:Here, I review the extent and significance of brain somatic mutations and provide my perspective regarding these mutations as potential molecular lesions underlying relatively common conditions with disrupted brain connectivity.
autism	disease	developmental disorder	2	0	15749246|9648034	PMID:15749246; Original text:Autism is a complex developmental disorder without an established single etiology but with significant contributions from genetic studies, functional research, and neuropsychiatric and neuroradiologic investigations.|PMID:9648034; Original text:Describes treatment of autism, a severe, chronic developmental disorder that results in significant lifelong disability for most persons, with few persons ever functioning in an independent and typical lifestyle.
ataxia syndrome	disease	fragile x syndrome	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x syndrome	disease	ovarian insufficiency	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x syndrome	disease	tremor	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x	disease	fragile x syndrome	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
ataxia syndrome	disease	ovarian insufficiency	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
ataxia syndrome	disease	tremor	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
ataxia syndrome	disease	fragile x	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
ovarian insufficiency	disease	tremor	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x	disease	ovarian insufficiency	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x	disease	tremor	1	0	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
impressions	disease	irritability	1	0	19858761	PMID:19858761; Original text:Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, combined treatment showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04).
hyperactivity	disease	impressions	1	0	19858761	PMID:19858761; Original text:Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, combined treatment showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04).
epilepsy	disease	mental retardation	1	0	19319661	PMID:19319661; Original text:The most significant clinical features were mental retardation, epilepsy and autistic behaviour, and these symptoms did not worsen, in contrast to other reports.
autistic behaviour	disease	mental retardation	1	0	19319661	PMID:19319661; Original text:The most significant clinical features were mental retardation, epilepsy and autistic behaviour, and these symptoms did not worsen, in contrast to other reports.
autistic behaviour	disease	epilepsy	1	0	19319661	PMID:19319661; Original text:The most significant clinical features were mental retardation, epilepsy and autistic behaviour, and these symptoms did not worsen, in contrast to other reports.
pervasive developmental disorders	disease	sleep disturbance	1	0	21570809	PMID:21570809; Original text:Sleep disturbance is a significant problem in the general pediatric population, and it occurs even more frequently in children with pervasive developmental disorders (pervasive developmental disorders).
infertility	disease	obese	1	0	31767240	PMID:31767240; Original text:Meta-analysis was only possible for infertility which was significantly more prevalent in obese (OR=1.49 95%CI 1.30-1.70) and overweight (OR=1.18 95%CI 1.11-1.26) men.
substance abuse	disease	trauma	1	0	17574799	PMID:17574799; Original text:Female survivors of childhood abuse did not improve in treatment as much as their nonabused peers in psychological functioning (p < .001), substance abuse (p < .01), or continuing trauma exposure (p < .01) .
autism	disease	cognitive impairment	2	0	10425586|10425586	PMID:10425586; Original text:This review addresses the issues and challenges related to the differential diagnosis of autism in preschool children with significant cognitive impairment.|PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.
autism	disease	mental retardation	6	0	10425586|9813776|21219265|19736351|23471985|3052070	"PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.|PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.|PMID:21219265; Original text:The risk was also very significant for autism associated with mental retardation.|PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).|PMID:23471985; Original text:As a posthoc analysis, we conducted genome-wide association scans on several organizational and topological network measures derived from the matrices to discover variants in and around genes associated with autism (autism), development (NEDD4), and mental retardation (UBE2A) significantly associated with connectivity.|PMID:3052070; Original text:We examined 31 studies which investigated the association of fra(X) syndrome with either inherited mental retardation or ""autism"" and found that the conclusion of those researchers could be significantly affected by sample size."
autism	disease	cognitive	1	0	10425586	PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.
cognitive impairment	disease	mental retardation	1	0	10425586	PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.
cognitive	disease	mental retardation	1	0	10425586	PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.
cognitive	disease	cognitive impairment	1	0	10425586	PMID:10425586; Original text:Issues affecting differential diagnosis include the use of traditional diagnostic guidelines for preschoolers with developmental delays, developmental changes in behavioral characteristics, the involvement of cognitive factors in symptom expression, and the overlap between autism and mental retardation in individuals with significant cognitive impairment.
asd	disease	autism spectrum disorders	3	0	24391123|31665947|25246292	PMID:24391123; Original text:Dental care is a significant unmet health care need for children with autism spectrum disorders (ASD).|PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.|PMID:25246292; Original text:Coa statistically significant pooled treatment effect sizenitive-behavioral therapy (Coa statistically significant pooled treatment effect sizenitive-behavioral therapy) has been developed and modified to treat anxiety symptoms in youth with hia statistically significant pooled treatment effect sizeh-functionina statistically significant pooled treatment effect size autism spectrum disorders (ASD) but has yielded varyina statistically significant pooled treatment effect size findina statistically significant pooled treatment effect sizes.
autism spectrum disorder	disease	behavioral disturbance	1	0	24231171	PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.
behavioral disturbance	disease	intellectual disability	1	0	24231171	PMID:24231171; Original text:For children diagnosed with an autism spectrum disorder and/or intellectual disability, the co-occurrence of serious behavioral disturbance can pose significant health and safety risks, impede normal learning and development, and put great stress on family systems.
compulsion	disease	repetitive behaviors	1	0	22193531	PMID:22193531; Original text:Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and the Clinical Global Impression rating of obsessive-compulsive symptoms, as well as on the the Clinical Global Impression overall improvement rating.
compulsion	disease	obsessive-compulsive symptoms	1	0	22193531	PMID:22193531; Original text:Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and the Clinical Global Impression rating of obsessive-compulsive symptoms, as well as on the the Clinical Global Impression overall improvement rating.
obsessive-compulsive symptoms	disease	repetitive behaviors	1	0	22193531	PMID:22193531; Original text:Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and the Clinical Global Impression rating of obsessive-compulsive symptoms, as well as on the the Clinical Global Impression overall improvement rating.
anger	disease	autistic symptoms	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
anxiety	disease	irritability	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease	irritability	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease	depression	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
depression	disease	hyperactivity	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
aggression	disease	anxiety	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease	anxiety	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anxiety	disease	hyperactivity	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease	autism	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
autism	disease	hyperactivity	2	0	9934941|32168067	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.|PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
aggression	disease	anger	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
aggression	disease	hyperactivity	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
anger	disease	hyperactivity	1	0	9934941	PMID:9934941; Original text:Significant improvements in overall symptoms of autism, motor restlessness or hyperactivity, social relatedness, affectual reactions, sensory responses, language usage, self-injurious behavior, aggression, irritability or anger, anxiety, and depression were observed.
autistic	disease	nutritional deficiencies	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
catatonia	disease	psychiatric	1	0	16697303	PMID:16697303; Original text:Catatonia should be assessed in any patient with spectrum disorders when there is an obvious and marked deterioration in movement, pattern of activities, self-care, and practical skills, compared with previous levels, through a comprehensive diagnostic evaluation of medical and psychiatric symptoms.
psychiatric	disease	spectrum disorders	1	0	16697303	PMID:16697303; Original text:Catatonia should be assessed in any patient with spectrum disorders when there is an obvious and marked deterioration in movement, pattern of activities, self-care, and practical skills, compared with previous levels, through a comprehensive diagnostic evaluation of medical and psychiatric symptoms.
catatonia	disease	spectrum disorders	1	0	16697303	PMID:16697303; Original text:Catatonia should be assessed in any patient with spectrum disorders when there is an obvious and marked deterioration in movement, pattern of activities, self-care, and practical skills, compared with previous levels, through a comprehensive diagnostic evaluation of medical and psychiatric symptoms.
mental health	disease	mental health problems	2	0	16670650|16670650	PMID:16670650; Original text:Both treatments resulted in significant and progressive improvement in overall mental health at follow-up (F = 2, 97, p =.007) and mental health significantly improved over time in the 54% of principal caregivers who had the highest levels of mental health problems.|PMID:16670650; Original text:A 20-week parent education and skills training program for parents of young children newly diagnosed with autism provides significant improvements in parental mental health and adjustment, justifying its addition to early intervention programs at least for parents with mental health problems.
autism	disease	mental health	1	0	16670650	PMID:16670650; Original text:A 20-week parent education and skills training program for parents of young children newly diagnosed with autism provides significant improvements in parental mental health and adjustment, justifying its addition to early intervention programs at least for parents with mental health problems.
autism	disease	mental health problems	1	0	16670650	PMID:16670650; Original text:A 20-week parent education and skills training program for parents of young children newly diagnosed with autism provides significant improvements in parental mental health and adjustment, justifying its addition to early intervention programs at least for parents with mental health problems.
agoraphobia	disease	panic attacks	1	0	9169302	PMID:9169302; Original text:Frequency and severity of panic attacks and severity of agoraphobia declined significantly with inositol compared to placebo.
autism spectrum disorder	disease	substance use disorder	2	0	32471596|33526236	PMID:32471596; Original text:Individuals with autism spectrum disorder (disorder) have a significantly higher risk for developing a substance use disorder (a substance use disorder) than the general population yet literature addressing cooccurring disorder and a substance use disorder is scarce.|PMID:33526236; Original text:Individuals with autism spectrum disorder (disorder) have a significantly higher risk for developing a substance use disorder (a substance use disorder) than the general population yet literature addressing cooccurring disorder and a substance use disorder is scarce.
autistic	disease	cognitive and behavioral impairments	1	0	21826280	PMID:21826280; Original text:We propose that alteration of the expression and/or timing of critical period circuit refinement in primary sensory brain areas may significantly contribute to autistic phenotypes, including cognitive and behavioral impairments.
agitation	disease	irritability	1	0	23782127	PMID:23782127; Original text:The ABC irritability/agitation subscale (subscale 1) was significantly improved from 8 weeks, and the hyperactivity/noncompliance subscale (subscale 4) was significantly improved in 12 weeks.
agitation	disease	hyperactivity	1	0	23782127	PMID:23782127; Original text:The ABC irritability/agitation subscale (subscale 1) was significantly improved from 8 weeks, and the hyperactivity/noncompliance subscale (subscale 4) was significantly improved in 12 weeks.
schizoid	disease	stimulatory	1	0	8463192	PMID:8463192; Original text:Asperger subjects tended to look less at the other person, to make more self-stimulatory gestures, and to look at the interviewer significantly less than normal subjects, and substantially less than schizoid subjects, during the periods when the interviewer was vocalizing although there were no such differences when the interviewer was listening.
autism	disease	epilepsy	1	0	19454962	PMID:19454962; Original text:However, critical review of the literature reveals that the rate in idiopathic cases with normal lower intelligence quotient is still significantly above the population risk suggesting that autism itself is associated with an increased risk of epilepsy.
autism spectrum disorder	disease	autoimmune disease	1	0	31191521	PMID:31191521; Original text:For example, mothers of children with Autism Spectrum Disorder (Autism Spectrum Disorder) are significantly more likely to have an autoimmune disease than women of neurotypically developing children.
gdm	disease	pgdm	1	0	25783684	PMID:25783684; Original text:Pregestational and gestational diabetes mellitus (PGDM; GDM) are significant health concerns because they are associated with an increased rate of malformations and maternal health complications.
gdm	disease	pregestational	1	0	25783684	PMID:25783684; Original text:Pregestational and gestational diabetes mellitus (PGDM; GDM) are significant health concerns because they are associated with an increased rate of malformations and maternal health complications.
gdm	disease	malformations	1	0	25783684	PMID:25783684; Original text:Pregestational and gestational diabetes mellitus (PGDM; GDM) are significant health concerns because they are associated with an increased rate of malformations and maternal health complications.
pgdm	disease	pregestational	1	0	25783684	PMID:25783684; Original text:Pregestational and gestational diabetes mellitus (PGDM; GDM) are significant health concerns because they are associated with an increased rate of malformations and maternal health complications.
malformations	disease	pgdm	1	0	25783684	PMID:25783684; Original text:Pregestational and gestational diabetes mellitus (PGDM; GDM) are significant health concerns because they are associated with an increased rate of malformations and maternal health complications.
malformations	disease	pregestational	1	0	25783684	PMID:25783684; Original text:Pregestational and gestational diabetes mellitus (PGDM; GDM) are significant health concerns because they are associated with an increased rate of malformations and maternal health complications.
cognitive or psychiatric symptoms	disease	posterior fossa arachnoid cyst	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
cognitive or psychiatric symptoms	disease	neurodevelopmental or psychiatric symptoms	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
neurodevelopmental or psychiatric symptoms	disease	posterior fossa arachnoid cyst	1	0	31321675	PMID:31321675; Original text:While it is reasonable to consider that there may be a causal relationship between a posterior fossa arachnoid cyst and neurodevelopmental or psychiatric symptoms in some patients, there is also a nontrivial prevalence of a posterior fossa arachnoid cyst in the asymptomatic population and a significant possibility that many a posterior fossa arachnoid cyst are incidental findings in the context of primary cognitive or psychiatric symptoms.
aseptic meningitis	disease	rubella	1	0	22336803	PMID:22336803; Original text:The highest risk of association with aseptic meningitis was observed within the third week after immunisation with Urabe-containing rubella (risk ratio (risk ratio) 14.28; 95% confidence interval (95% confidence interval) from 7.93 to 25.71) and within the third (risk ratio 22.5; 95% 95% confidence interval 11.8 to 42.9) or fifth (risk ratio 15.6; 95% 95% confidence interval 10.3 to 24.2) weeks after immunisation with the vaccine prepared with the Leningrad-Zagreb strain.
autism-spectrum disorders	disease	schizophrenia	1	0	29688876	PMID:29688876; Original text:Specifically, cortical thickness showed significant enrichment between patients with if autism-spectrum disorders and those with attention-deficit/hyperactivity disorder in the default mode network, between patients with if autism-spectrum disorders and those with schizophrenia in the frontoparietal and limbic networks, and between patients with attention-deficit/hyperactivity disorder and those with schizophrenia in the ventral attention network.
social anxiety	disease	social anxiety disorder	1	0	12462859	PMID:12462859; Original text:Social anxiety disorder is well suited to the spectrum concept because it has trait-like qualities of early onset, chronicity, and no empirically derived threshold that demarcates normal from clinically significant trait social anxiety.
social	disease	social anxiety disorder	1	0	12462859	PMID:12462859; Original text:For several other disorders that share a prominent focus on social comparison, significant subgroups of patients seem to have features of social anxiety disorder.
irritability	disease	stereotyped behavior	1	0	18685284	PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).
lethargy	disease	stereotyped behavior	1	0	18685284	PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).
inappropriate speech	disease	stereotyped behavior	1	0	18685284	PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).
hyperactivity	disease	stereotyped behavior	1	0	18685284	PMID:18685284; Original text:Paired comparison of baseline and 13-week endpoint scores showed significant reductions in Aberrant Behavior Checklist subscale scores for irritability (p < 0.0001), lethargy (p < 0.0001), stereotyped behavior (p < 0.005), hyperactivity (p < 0.0001) and inappropriate speech (p < 0.005).
mitochondrial dysfunction	disease	neuronal apoptosis	1	0	33493659	PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.
psychiatric	disease	t2dm	1	0	26792761	PMID:26792761; Original text:Similarly, compared with psychiatric controls, antipsychotic-exposed youth had significantly higher cumulative T2DM risk (OR, 2.09; 95% CI, 1.50-52.90; P < .0001) and incidence rate ratio (incidence rate ratio, 1.79; 95% CI, 1.31-2.44; P < .0001).
autism spectrum disorder	disease	t2dm	1	0	26792761	PMID:26792761; Original text:Greater T2DM incidence was associated with second-generation antipsychotic prescription (P ≤ .050) and less autism spectrum disorder diagnosis (P = .048)
attention-deficit/hyperactivity disorder	disease	neurological problems	1	0	33372183	PMID:33372183; Original text:Neurological problems were significantly associated with a diagnosis of Attention-deficit/hyperactivity disorder.
asperger	disease	autistic	1	0	9690938	PMID:9690938; Original text:The autistic group's performance on the false belief, belief term comprehension, and belief term expression tasks was significantly poorer than that of the Asperger, language impaired, and normal groups.
's disease	disease	alzheimer	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
alzheimer	disease	cognitive impairment	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
alzheimer	disease	schizophrenia	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
alzheimer	disease	snippet	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
's disease	disease	cognitive impairment	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
's disease	disease	schizophrenia	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
's disease	disease	snippet	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
cognitive impairment	disease	schizophrenia	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
cognitive impairment	disease	snippet	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
schizophrenia	disease	snippet	1	0	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
alcoholic disorder	disease	autism spectrum disorder	1	0	34358505	PMID:34358505; Original text:A network analysis presented using genes summarized in this review, further show a significant association with disorders such as major depressive disorder, alcoholic disorder, psychotic disorders and autism spectrum disorder.
alcoholic disorder	disease	depressive disorder	1	0	34358505	PMID:34358505; Original text:A network analysis presented using genes summarized in this review, further show a significant association with disorders such as major depressive disorder, alcoholic disorder, psychotic disorders and autism spectrum disorder.
alcoholic disorder	disease	psychotic disorders	1	0	34358505	PMID:34358505; Original text:A network analysis presented using genes summarized in this review, further show a significant association with disorders such as major depressive disorder, alcoholic disorder, psychotic disorders and autism spectrum disorder.
autism spectrum disorder	disease	depressive disorder	1	0	34358505	PMID:34358505; Original text:A network analysis presented using genes summarized in this review, further show a significant association with disorders such as major depressive disorder, alcoholic disorder, psychotic disorders and autism spectrum disorder.
autism spectrum disorder	disease	psychotic disorders	1	0	34358505	PMID:34358505; Original text:A network analysis presented using genes summarized in this review, further show a significant association with disorders such as major depressive disorder, alcoholic disorder, psychotic disorders and autism spectrum disorder.
depressive disorder	disease	psychotic disorders	1	0	34358505	PMID:34358505; Original text:A network analysis presented using genes summarized in this review, further show a significant association with disorders such as major depressive disorder, alcoholic disorder, psychotic disorders and autism spectrum disorder.
autism	disease	tuberous sclerosis	4	0	15542389|32563542|10473304|9813776	PMID:15542389; Original text:Incidence of autism associated with Tuberous Sclerosis may be significantly higher than the rates of cardiac and renal abnormalities, for which screening is routinely conducted in this population.|PMID:32563542; Original text:Recently, significant progress has been possible with the prospective calculation of the prevalence of autism in Tuberous sclerosis complex, identification of early clinical and neurophysiological biomarkers to predict autism, and investigation of different therapies to prevent autism in this high-risk population.|PMID:10473304; Original text:On average, medical conditions of potential causal significance were found in 6% of subjects with autism, with tuberous sclerosis having a consistently strong association with autism.|PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
autism	disease	cardiac and renal abnormalities	1	0	15542389	PMID:15542389; Original text:Incidence of autism associated with Tuberous Sclerosis may be significantly higher than the rates of cardiac and renal abnormalities, for which screening is routinely conducted in this population.
cardiac and renal abnormalities	disease	tuberous sclerosis	1	0	15542389	PMID:15542389; Original text:Incidence of autism associated with Tuberous Sclerosis may be significantly higher than the rates of cardiac and renal abnormalities, for which screening is routinely conducted in this population.
mental	disease	mental disorders	1	0	31914909	PMID:31914909; Original text:Pro and their nutrient sources can improve mental health and psychological function and can be offered as new medicines for common mental disorders, however, more clinical studies are necessary to conduct regarding the clinical significance of the effects and their bioequivalence or superiority against current treatments.
dysmorphic features	disease	focal epilepsy	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
focal epilepsy	disease	repetitive behaviours	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
deficient expressive language	disease	focal epilepsy	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
focal epilepsy	disease	intellectual disability	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
dysmorphic features	disease	repetitive behaviours	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
deficient expressive language	disease	dysmorphic features	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
dysmorphic features	disease	intellectual disability	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
deficient expressive language	disease	repetitive behaviours	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
intellectual disability	disease	repetitive behaviours	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
deficient expressive language	disease	intellectual disability	1	0	23727450	PMID:23727450; Original text:Our subject displays severely deficient expressive language, stereotypic and repetitive behaviours, mild intellectual disability (mild intellectual disability), focal epilepsy, short stature and absence of significant dysmorphic features.
constipation	disease	diarrhea	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
constipation	disease	indigestion	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
constipation	disease	in	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
abdominal pain	disease	constipation	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
diarrhea	disease	indigestion	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
diarrhea	disease	in	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
abdominal pain	disease	diarrhea	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
in	disease	indigestion	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
abdominal pain	disease	indigestion	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
abdominal pain	disease	in	1	0	28122648	PMID:28122648; Original text:The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.
brain abnormalities	disease	learning disability	1	0	9463598	PMID:9463598; Original text:Brain abnormalities can be detected in cases of idiopathic and non-idiopathic learning disability, but their significance is not clear due to discrepancies in study findings and the small cohorts involved.
bulimia nervosa	disease	ptsd	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
asd	disease	ptsd	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
polycystic ovary syndrome	disease	ptsd	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
asd	disease	bulimia nervosa	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
bulimia nervosa	disease	polycystic ovary syndrome	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
asd	disease	polycystic ovary syndrome	1	0	34499230	PMID:34499230; Original text:In ASD, bulimia nervosa, and PTSD samples, significantly increased rates of Polycystic ovary syndrome were reported compared with healthy control samples, although studies were relatively small.
autism	disease	constipation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
constipation	disease	diarrhea).areas	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
asd	disease	constipation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism spectrum disorders	disease	constipation	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism	disease	diarrhea).areas	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism	disease	autism spectrum disorders	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
asd	disease	diarrhea).areas	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
autism spectrum disorders	disease	diarrhea).areas	1	0	31665947	PMID:31665947; Original text:Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (Microbiota Transplant Therapy), a type of intensive intestinal microbiota transplantation (intensive intestinal microbiota transplantation), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews intensive intestinal microbiota transplantation, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive Microbiota Transplant Therapy for autism.
developmental disorders	disease	weight gain	1	0	17069543	PMID:17069543; Original text:Olanzapine may be a promising treatment for improving global functioning of pervasive developmental disorders, but the risk of significant weight gain remains a concern.
psychiatric	disease	psychiatric disease	1	0	34057596	PMID:34057596; Original text:The significance of serum neural autoantibodies associated with psychiatric symptoms in children remains often unclear, but might be relevant for the extent and occurrence of psychiatric disease manifestation in later life, as well as therapy and outcome.
autism spectrum disorders	disease	obsessive-compulsive behaviors	1	0	31638682	PMID:31638682; Original text:In this preliminary study of children and adolescents with autism spectrum disorders, treatment with fluoxetine compared with placebo resulted in significantly lower scores for obsessive-compulsive behaviors at 16 weeks.
attention	disease	hyperactivity	1	0	27278054	PMID:27278054; Original text:Both groups showed a significant improvement in attention-deficit/hyperactivity disorder symptoms after 24 weeks of treatment (attention-deficit/hyperactivity disorder Rating Scale, Conners Parent Rating Scale-Hyperactivity, and Clinical Global Improvement-Severity Scale).
attention-deficit hyperactivity disorder	disease	autism spectrum disorders	3	0	23123089|23123089|23123089	PMID:23123089; Original text:Use of the a frequency modulation system resulted in significant average improvements in speech recognition in noise for the children with autism spectrum disorders and attention-deficit hyperactivity disorder as well as large effect sizes.|PMID:23123089; Original text:When compared to typically functioning peers, children with autism spectrum disorders and attention-deficit hyperactivity disorder had significantly poorer average speech recognition performance in noise without the a frequency modulation system but comparable average performance when the a frequency modulation system was used.|PMID:23123089; Original text:Given the significantly better speech recognition in noise, increased on-task behaviors, and improved teacher ratings of listening behaviors with the a frequency modulation system, these devices may be a viable option for children who have autism spectrum disorders and attention-deficit hyperactivity disorder in the classroom.
hyperactive behavior	disease	hyperactivity	1	0	32381101	PMID:32381101; Original text:A favorable effect was also found for social behavior (Social Responsiveness Scale) (t(11) = 4.01, p = .002, d = .549) and hyperactive behavior (ABC-hyperactivity subscale) (t(12) = 3.65, p = .003, d = .686).
autism	disease	chromosomal abnormalities	2	0	15121991|11525418	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.|PMID:11525418; Original text:These data support the contribution of chromosomal abnormalities to a small but significant number of cases of autism, and highlight the involvement of chromosome 15 and the sex chromosomes.
autism	disease	chromosomal	1	0	15121991	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.
chromosomal	disease	chromosomal abnormalities	1	0	15121991	PMID:15121991; Original text:There are 3 main approaches to identifying genetic loci, chromosomal regions likely to contain relevant genes: 1) whole genome screens, searching for linkage of autism to shared genetic markers in populations of multiplex families (families with >1 affected family member; 2) cytogenetic studies that may guide molecular studies by pointing to relevant inherited or de novo chromosomal abnormalities in affected individuals and their families; and 3) evaluation of candidate genes known to affect brain development in these significantly linked regions or, alternatively, linkage of candidate genes selected a priori because of their presumptive contribution to the pathogenesis of autism.
hemiplegia	disease	tri	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
diplegia	disease	tri	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
spasticity	disease	tri	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease	tri	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
intellectual disability	disease	tri	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
quadriplegia	disease	tri	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
diplegia	disease	hemiplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
hemiplegia	disease	spasticity	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease	hemiplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
hemiplegia	disease	intellectual disability	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
hemiplegia	disease	quadriplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
diplegia	disease	spasticity	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease	diplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
diplegia	disease	intellectual disability	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
diplegia	disease	quadriplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease	spasticity	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
intellectual disability	disease	spasticity	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
quadriplegia	disease	spasticity	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease	intellectual disability	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
communication disorders	disease	quadriplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
intellectual disability	disease	quadriplegia	1	0	31018221	PMID:31018221; Original text:Type of spasticity (hemiplegia > diplegia > tri/quadriplegia; OR [odds ratio] = 1.76, SE [standard error] = 0.2785, p = 0.04), communication disorders (OR = 7.442, SE = 0.59, p < 0.001), intellectual disability (OR = 2.27, SE = 0.43, p = 0.05), feeding abilities (OR = 0.35, SE = 0.35, p = 0.002), and motor function (OR = 0.59, SE = 0.22, p = 0.01) were significantly associated with disorder.
autism spectrum disorders	disease	functional impairment	1	0	19309326	PMID:19309326; Original text:Children with autism spectrum disorders often present with comorbid anxiety disorders that cause significant functional impairment.
anxiety disorders	disease	autism spectrum disorders	1	0	19309326	PMID:19309326; Original text:Children with autism spectrum disorders often present with comorbid anxiety disorders that cause significant functional impairment.
anxiety disorders	disease	functional impairment	1	0	19309326	PMID:19309326; Original text:Children with autism spectrum disorders often present with comorbid anxiety disorders that cause significant functional impairment.
ear-occlusion	disease	hyperactivity	1	0	10755175	PMID:10755175; Original text:Significant differences tended to show that the control condition was superior on parent-rated measures of hyperactivity and on direct observational measures of ear-occlusion.
mitochondrial disease	disease	seizures	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease	mitochondrial disease	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
mitochondrial disease	disease	motor delay	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease	mitochondrial disease	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
gastrointestinal abnormalities	disease	mitochondrial disease	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease	seizures	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
motor delay	disease	seizures	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease	seizures	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
gastrointestinal abnormalities	disease	seizures	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease	motor delay	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease	developmental regression	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
developmental regression	disease	gastrointestinal abnormalities	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease	motor delay	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
gastrointestinal abnormalities	disease	motor delay	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
asd	disease	gastrointestinal abnormalities	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
autism	disease	hyperhomocysteinemia	1	0	27755291	PMID:27755291; Original text:The meta-analysis of nine studies showed hyperhomocysteinemia as a significant risk factor for autism in both fixed-effects (P<0.0001) and random-effects (P=0.026) models.
dietdhd	disease	dietdos	1	0	20406576	PMID:20406576; Original text:diett this point, there was a significant improvement to mean diet group scores (time*treatment interaction) on sub-domains of dietDOS, GdietRS and dietDHD-IV measures.
weight gain	disease	weight loss	1	0	10933118	PMID:10933118; Original text:Weight gain was common, although the rate of increase lessened over a period of time; after drug withdrawal, considerable weight loss was observed in the patient who had previously shown the most significant increase.
anxiety	disease	ocd	1	0	23389964	PMID:23389964; Original text:Both treatments produced a significant reduction in particularly obsessive compulsive disorder symptoms, within-group effect sizes of 1.01 Group cognitive behavioral treatment group and 0.6 for the OCD or anxiety management group.
obsessive compulsive disorder	disease	ocd	1	0	23389964	PMID:23389964; Original text:Both treatments produced a significant reduction in particularly obsessive compulsive disorder symptoms, within-group effect sizes of 1.01 Group cognitive behavioral treatment group and 0.6 for the OCD or anxiety management group.
anxiety	disease	obsessive compulsive disorder	1	0	23389964	PMID:23389964; Original text:Both treatments produced a significant reduction in particularly obsessive compulsive disorder symptoms, within-group effect sizes of 1.01 Group cognitive behavioral treatment group and 0.6 for the OCD or anxiety management group.
asd	disease	obsessive-compulsive disorder symptomology	1	0	29082426	PMID:29082426; Original text:However, the significant overlap of ASD features with anxiety and obsessive-compulsive disorder symptomology makes differential diagnosis of these disorders particularly challenging.
anxiety	disease	obsessive-compulsive disorder symptomology	1	0	29082426	PMID:29082426; Original text:However, the significant overlap of ASD features with anxiety and obsessive-compulsive disorder symptomology makes differential diagnosis of these disorders particularly challenging.
anxiety	disease	asd	4	0	29082426|25424398|25246292|25602249	PMID:29082426; Original text:However, the significant overlap of ASD features with anxiety and obsessive-compulsive disorder symptomology makes differential diagnosis of these disorders particularly challenging.|PMID:25424398; Original text:Thirty-one children (11-16 years) with ASD and clinically significant anxiety were randomly assigned to receive 16 weekly a personalized, modular cognitive-behavioral therapy sessions or an equivalent duration of TAU.|PMID:25246292; Original text:The present report is a systematic review and meta-analysis examinina statistically significant pooled treatment effect size the efficacy of Coa statistically significant pooled treatment effect sizenitive-behavioral therapy for anxiety amona statistically significant pooled treatment effect size youth with ASD.|PMID:25602249; Original text:It is well established that the prevalence of anxiety in youth with an ASD is significantly greater than the prevalence of anxiety in the general population.
autism	disease	neurodevelopmental disorders	3	0	30563709|15090875|20969835	PMID:30563709; Original text:Advances in sequencing technology have significantly expanded our understanding of the genetics of autism and neurodevelopmental disorders (neurodevelopmental disorders).|PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.|PMID:20969835; Original text:We present initial evidence offering proof of concept that brain anatomy can be used to accurately distinguish adults with autism from healthy controls, and from some other neurodevelopmental disorders (some other neurodevelopmental disorders).
autism	disease	disruptive behavior	1	0	24061784	PMID:24061784; Original text:Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12.
autism	disease	mood	1	0	24061784	PMID:24061784; Original text:Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12.
disruptive behavior	disease	mood	1	0	24061784	PMID:24061784; Original text:Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12.
asd	disease	social-emotional problems	1	0	33888566	PMID:33888566; Original text:These findings indicate that cognitive behavioral therapy may significantly improve the symptoms of ASD and social-emotional problems in children or adolescents with ASD.
epilepsy	disease	seizures	1	0	33200402	PMID:33200402; Original text:The highest diagnostic yield for epilepsy subtypes was observed in individuals with intellectual disability (27.9%) and early onset seizures (36.8%).
epilepsy	disease	intellectual disability	3	0	33200402|24123946|18565495	PMID:33200402; Original text:The highest diagnostic yield for epilepsy subtypes was observed in individuals with intellectual disability (27.9%) and early onset seizures (36.8%).|PMID:24123946; Original text:The del15q11.2 was found to be significantly associated with intellectual disability, schizophrenia, epilepsy, and disorder.|PMID:18565495; Original text:There was a strong discrepancy in relative risk (relative risk) according to IQ, with more autistic patients with intellectual disability having epilepsy (relative risk = .555; 95% confidence interval [CI]: .42-.73; p < .001).
intellectual disability	disease	seizures	1	0	33200402	PMID:33200402; Original text:The highest diagnostic yield for epilepsy subtypes was observed in individuals with intellectual disability (27.9%) and early onset seizures (36.8%).
anxiety symptoms	disease	autism spectrum disorders	1	0	25246292	PMID:25246292; Original text:Coa statistically significant pooled treatment effect sizenitive-behavioral therapy (Coa statistically significant pooled treatment effect sizenitive-behavioral therapy) has been developed and modified to treat anxiety symptoms in youth with hia statistically significant pooled treatment effect sizeh-functionina statistically significant pooled treatment effect size autism spectrum disorders (ASD) but has yielded varyina statistically significant pooled treatment effect size findina statistically significant pooled treatment effect sizes.
anxiety symptoms	disease	asd	1	0	25246292	PMID:25246292; Original text:Coa statistically significant pooled treatment effect sizenitive-behavioral therapy (Coa statistically significant pooled treatment effect sizenitive-behavioral therapy) has been developed and modified to treat anxiety symptoms in youth with hia statistically significant pooled treatment effect sizeh-functionina statistically significant pooled treatment effect size autism spectrum disorders (ASD) but has yielded varyina statistically significant pooled treatment effect size findina statistically significant pooled treatment effect sizes.
autism spectrum	disease	linguistic and motor impairments	1	0	28685955	PMID:28685955; Original text:Children with autism spectrum disorder (disorder) show significant linguistic and motor impairments compared to children with typical development (typical development).
anxiety	disease	tension	1	0	10200837	PMID:10200837; Original text:Behavioral results indicated a significant reduction in tension and a marginally significant reduction in anxiety for children who received the deep pressure compared with the children who did not.
autistic	disease	epileptic seizures	1	0	1708491	PMID:1708491; Original text:A significant proportion of autistic children experience epileptic seizures and have abnormal EEGs.
inadequate eye contact	disease	irritability	1	0	22419332	PMID:22419332; Original text:In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms.
inadequate eye contact	disease	inappropriate speech	1	0	22419332	PMID:22419332; Original text:In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms.
hyperactivity	disease	inadequate eye contact	1	0	22419332	PMID:22419332; Original text:In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms.
irritability	disease	stereotypy	3	0	32168067|19284641|32947424	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
autism	disease	stereotypy	1	0	32168067	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
lethargy	disease	stereotypy	1	0	32168067	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
hyperactivity	disease	stereotypy	3	0	32168067|19284641|32947424	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).|PMID:19284641; Original text:On the Aberrant Behavior Checklist, significant improvements were observed in the tre1.3 atmosphereent group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.|PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
autism	disease	lethargy	1	0	32168067	PMID:32168067; Original text:Repeated-measures analysis demonstrated significant effect for time-treatment interaction in the Childhood Autism Rating Scale (F (1, 2.23) = 13.22, P < 0.001), as well as 4 subscales of the ABC-C including: irritability (F (1, 2.12) = 3.84, P = 0.026), hyperactivity (F (1, 2.09) = 3.56, P = 0.039), lethargy (F (1, 2.18) = 31.50, P < 0.001), and stereotypy (F (1, 1.89) = 4.04, P = 0.026).
eating disorders	disease	obsessive-compulsive disorder	1	0	32503201	PMID:32503201; Original text:(Obsessive-Compulsive Disorder), one on Schizophrenia (Schizophrenia) and one on Eating Disorders (Eating Disorders).
eating disorders	disease	schizophrenia	1	0	32503201	PMID:32503201; Original text:(Obsessive-Compulsive Disorder), one on Schizophrenia (Schizophrenia) and one on Eating Disorders (Eating Disorders).
anorexia nervosa	disease	autism spectrum disorder	1	0	26542816	PMID:26542816; Original text:Seven studies were identified and subsequent meta-analysis indicated that those with Anorexia Nervosa appear to have significant difficulties of a manner characteristic of Autism Spectrum Disorder, relative to controls.
attention-deficit/hyperactivity disorder	disease	autism	3	0	23782128|15090875|27988864	PMID:23782128; Original text:(DSM-IV-TR) criteria for an autism spectrum disorder (disorder) on the Autism Diagnostic Interview-Revised (-Revised) and the Autism Diagnostic Observation Schedule (the Autism Diagnostic Observation Schedule), and had significant symptoms of attention-deficit/hyperactivity disorder (attention-deficit/hyperactivity disorder).|PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.|PMID:27988864; Original text:The majority of studies on attention-deficit/hyperactivity disorder (attention-deficit/hyperactivity disorder) and autism found a significant decrease in acid levels in patients versus healthy controls.
attention-deficit/hyperactivity disorder	disease	autism spectrum disorder	2	0	23782128|30658861	PMID:23782128; Original text:(DSM-IV-TR) criteria for an autism spectrum disorder (disorder) on the Autism Diagnostic Interview-Revised (-Revised) and the Autism Diagnostic Observation Schedule (the Autism Diagnostic Observation Schedule), and had significant symptoms of attention-deficit/hyperactivity disorder (attention-deficit/hyperactivity disorder).|PMID:30658861; Original text:Attention-Deficit/Hyperactivity Disorder (Attention-Deficit/Hyperactivity Disorder) and Autism Spectrum Disorder (Autism Spectrum Disorder) are both neurodevelopmental disorders originating in childhood with high associated impairments and public health significance.
anxiety	disease	conduct problem	1	0	20001837	PMID:20001837; Original text:However, results from the Conners' Parent Questionnaire revealed an improvement only for anxiety (p = 0.04) in the massage group, whereas when both groups were compared, a significant improvement in conduct problem (p = 0.03) and anxiety (p = 0.01) was found.
attention deficit hyperactivity disorder	disease	spectrum disorders	1	0	33403915	PMID:33403915; Original text:Given the significant clinical and genetic overlap between spectrum disorders and attention deficit hyperactivity disorder, surprisingly, no reviews have compared the clinical, developmental, and genetic correlates of in particular, the default mode network in spectrum disorders and attention deficit hyperactivity disorder and here we address this knowledge gap.
social	disease	social and attention problems	1	0	25804268	PMID:25804268; Original text:At post-treatment, participants showed significant improvements on all subscales of the Social Responsiveness Scale (P < 0.01) and the Social and Attention Problems syndrome scales of the Child Behavior Checklist (P < 0.05).
depression	disease	depressive symptoms	1	0	24408892	PMID:24408892; Original text:Results for treatment outcome suggest that the a treatment group showed significant improvement in communication and social interaction domain scores on the Autism Diagnostic Observation Schedule, interpersonal relationship and play/leisure time on the subdomain scores of the Korean version of the Vineland Adaptive Behavior Scale (p's < 0.01), social skills knowledge total scores on the Test of Adolescent Social Skills Knowledge-Revised (p < 0.01), and decreased depressive symptoms on the Child Depression Inventory following treatment (p < 0.05).
depression	disease	respiratory distress	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
preterm birth	disease	respiratory distress	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
convulsions	disease	respiratory distress	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
depression	disease	preterm birth	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
convulsions	disease	depression	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
convulsions	disease	preterm birth	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
maladaptive behavior	disease	repetitive thoughts	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
aggression	disease	maladaptive behavior	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
aggression	disease	repetitive thoughts	1	0	8911223	PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
attention-deficit/hyperactivity disorder	disease	psychiatrically	1	0	29675767	PMID:29675767; Original text:The majority of psychiatrically referred youth with disorder had positive Child Behavior Checklist-emotional dysregulation (CBCL-emotional dysregulation) profile that was significantly higher than in youth with attention-deficit/hyperactivity disorder (82 vs. 53%; p < 0.001).
emotional dysregulation	disease	semotional dysregulation	1	0	29675767	PMID:29675767; Original text:The severe emotional dysregulation (Semotional dysregulation) profile was significantly greater in disorder youth than attention-deficit/hyperactivity disorder (44 vs. 15%; p < 0.001).
attention-deficit/hyperactivity disorder	disease	semotional dysregulation	1	0	29675767	PMID:29675767; Original text:The severe emotional dysregulation (Semotional dysregulation) profile was significantly greater in disorder youth than attention-deficit/hyperactivity disorder (44 vs. 15%; p < 0.001).
attention-deficit/hyperactivity disorder	disease	emotional dysregulation	1	0	29675767	PMID:29675767; Original text:The severe emotional dysregulation (Semotional dysregulation) profile was significantly greater in disorder youth than attention-deficit/hyperactivity disorder (44 vs. 15%; p < 0.001).
irritability	disease	self	1	0	19519261	PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.
irritability	disease	tantrums	2	0	19519261|22549762	PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.|PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
aggression	disease	self	1	0	19519261	PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.
self	disease	tantrums	1	0	19519261	PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.
aggression	disease	tantrums	2	0	19519261|22549762	PMID:19519261; Original text:Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final the Clinical Global Impressions-Improvement of 1 or 2 (very much or much improved) and a 25% or greater improvement on the the Aberrant Behavior Checklist.|PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
alzheimer's disease	disease	autism spectrum disorders	1	0	28901249	PMID:28901249; Original text:In this review paper, an attempt to specify significant correlations between proteins linked to Autism Spectrum Disorders and Alzheimer's Disease is presented.
autism	disease	disability	1	0	9648034	PMID:9648034; Original text:Describes treatment of autism, a severe, chronic developmental disorder that results in significant lifelong disability for most persons, with few persons ever functioning in an independent and typical lifestyle.
developmental disorder	disease	disability	1	0	9648034	PMID:9648034; Original text:Describes treatment of autism, a severe, chronic developmental disorder that results in significant lifelong disability for most persons, with few persons ever functioning in an independent and typical lifestyle.
autism spectrum disorders	disease	respiratory sinus arrhythmia	2	0	32818581|32818581	PMID:32818581; Original text:respiratory sinus arrhythmia reactivity was significantly lower in autism spectrum disorders group for all situations, with the largest effect size for social stress (g=-0.7246, p < 0.0001).|PMID:32818581; Original text:Individuals with autism spectrum disorders had a significantly lower baseline Heart rate variability for parasympathetic indices in hierarchical order (Hedges'g=-0.5168, p < 0.0001) and respiratory sinus arrhythmia (g=-0.5860, p=0.0010).
asd	disease	schz	2	0	28314733|28314733	PMID:28314733; Original text:The poor understanding of the genetics of ASD and SCHZ is a significant hurdle to developing effective treatments for these costly conditions.|PMID:28314733; Original text:Continuous efforts to understand the genetic basis of ASD and SCHZ will soon lead to significant progress in the mechanistic understanding of these prominent psychiatric disorders and enable the development of disease-modifying therapies for these devastating conditions.
asd	disease	psychiatric disorders	1	0	28314733	PMID:28314733; Original text:Continuous efforts to understand the genetic basis of ASD and SCHZ will soon lead to significant progress in the mechanistic understanding of these prominent psychiatric disorders and enable the development of disease-modifying therapies for these devastating conditions.
psychiatric disorders	disease	schz	1	0	28314733	PMID:28314733; Original text:Continuous efforts to understand the genetic basis of ASD and SCHZ will soon lead to significant progress in the mechanistic understanding of these prominent psychiatric disorders and enable the development of disease-modifying therapies for these devastating conditions.
autistic disorder	disease	irritability	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
irritability	disease	self-injury	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
autistic disorder	disease	self-injury	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
aggression	disease	autistic disorder	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
autistic disorder	disease	tantrums	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
self-injury	disease	tantrums	1	0	22549762	PMID:22549762; Original text:Individuals with autistic disorder (autistic disorder) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury.
autistic disorders	disease	repetitive behaviors	1	0	10649829	PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
autism spectrum disorders	disease	communication deficit	1	0	26577688	PMID:26577688; Original text:We concluded that teaching Karate techniques to children with autism spectrum disorders leads to significant reduction in their communication deficit.
autism spectrum disorder	disease	neurological disorder	1	0	23965928	PMID:23965928; Original text:Autism spectrum disorder (disorder) is a neurological disorder in which a significant number of the children experience a developmental regression characterized by a loss of previously acquired skills and abilities.
autism spectrum disorder	disease	developmental regression	1	0	23965928	PMID:23965928; Original text:Autism spectrum disorder (disorder) is a neurological disorder in which a significant number of the children experience a developmental regression characterized by a loss of previously acquired skills and abilities.
developmental regression	disease	neurological disorder	1	0	23965928	PMID:23965928; Original text:Autism spectrum disorder (disorder) is a neurological disorder in which a significant number of the children experience a developmental regression characterized by a loss of previously acquired skills and abilities.
autism spectrum disorders	disease	neurodevelopmental disorders	1	0	28577609	PMID:28577609; Original text:Autism spectrum disorders (disorders) are neurodevelopmental disorders whose core features of impaired social communication and atypical repetitive behaviors and/or restrictions in range of interests emerge in toddlerhood and carry significant implications at successive stages of development.
neurodevelopmental disorders	disease	repetitive behaviors	1	0	28577609	PMID:28577609; Original text:Autism spectrum disorders (disorders) are neurodevelopmental disorders whose core features of impaired social communication and atypical repetitive behaviors and/or restrictions in range of interests emerge in toddlerhood and carry significant implications at successive stages of development.
impaired social communication	disease	neurodevelopmental disorders	1	0	28577609	PMID:28577609; Original text:Autism spectrum disorders (disorders) are neurodevelopmental disorders whose core features of impaired social communication and atypical repetitive behaviors and/or restrictions in range of interests emerge in toddlerhood and carry significant implications at successive stages of development.
autism spectrum disorders	disease	impaired social communication	1	0	28577609	PMID:28577609; Original text:Autism spectrum disorders (disorders) are neurodevelopmental disorders whose core features of impaired social communication and atypical repetitive behaviors and/or restrictions in range of interests emerge in toddlerhood and carry significant implications at successive stages of development.
impaired social communication	disease	repetitive behaviors	1	0	28577609	PMID:28577609; Original text:Autism spectrum disorders (disorders) are neurodevelopmental disorders whose core features of impaired social communication and atypical repetitive behaviors and/or restrictions in range of interests emerge in toddlerhood and carry significant implications at successive stages of development.
spectrum disorders	disease	wlc	1	0	28869842	PMID:28869842; Original text:The main results are as follows: (I) the spectrum disorders-EXP group showed significant improvement, compared to the spectrum disorders-WLC group, in their reading comprehension ability evidenced from change in comprehension scores; (II) the spectrum disorders-EXP group showed increased local brain connectivity in Reading Network regions compared to the spectrum disorders-WLC group post-intervention; (III) intervention-related changes in local brain connectivity were observed in the spectrum disorders-EXP from pre to post-intervention; and (IV) improvement in language comprehension significantly predicted changes in local connectivity.
autism spectrum disorder	disease	behavioural deficits	1	0	25149412	PMID:25149412; Original text:In the case-control study, 17 males with autism spectrum disorder showed significant behavioural deficits in inferring others' social emotions (P = 0.018) but not in inferring others' beliefs (P = 0.064) compared with 17 typically developing demographically-matched male participants.
autism	disease	gastrointestinal symptoms	1	0	32305492	PMID:32305492; Original text:An increase in beneficial bacteria (Bifidobacteriales and B. longum) and suppression of suspected pathogenic bacteria (suspected pathogenic bacteria) emerged after probiotics + FOS intervention, with significant reduction in the severity of autism and gastrointestinal symptoms.
dopamine metabolism disorder	disease	hyperserotonergic	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
asd	disease	dopamine metabolism disorder	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
asd	disease	hyperserotonergic	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
prader-willi syndrome disorder	disease	restricted or repetitive behaviors	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
prader-willi syndrome	disease	restricted or repetitive behaviors	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
restricted or repetitive behaviors	disease	social-communication impairment	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
prader-willi syndrome	disease	prader-willi syndrome disorder	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
prader-willi syndrome disorder	disease	social-communication impairment	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
prader-willi syndrome	disease	social-communication impairment	1	0	26331980	PMID:26331980; Original text:Individuals with Prader-Willi syndrome demonstrate significant levels of restricted or repetitive behaviors and social-communication impairment, in some reports reaching similar levels to those of non-Prader-Willi syndrome disorder comparison groups.
developmental delay/	disease	schizophrenia	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
autism spectrum disorder	disease	developmental delay/	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
developmental delay/	disease	neurodevelopmental psychiatric disorders	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
developmental delay/	disease	intellectual disability	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
neurodevelopmental psychiatric disorders	disease	schizophrenia	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
autism spectrum disorder	disease	neurodevelopmental psychiatric disorders	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
intellectual disability	disease	neurodevelopmental psychiatric disorders	1	0	33434711	PMID:33434711; Original text:Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (neurodevelopmental psychiatric disorders), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia.
autistic disorders	disease	pervasive developmental disorders	1	0	22650115	PMID:22650115; Original text:For this reason, the term spectrum points out the significance of the dimensional assessment of autistic disorders, which will most likely be the basis of the new diagnostic classification of the disorders belonging to the current group of pervasive developmental disorders in the new DSM-V classification.
autism	disease	tourette's syndrome	1	0	15090875	PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.
neurodevelopmental disorders	disease	tourette's syndrome	1	0	15090875	PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.
attention-deficit/hyperactivity disorder	disease	tourette's syndrome	1	0	15090875	PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.
attention-deficit/hyperactivity disorder	disease	neurodevelopmental disorders	2	0	15090875|30658861	PMID:15090875; Original text:Recent oculomotor studies have made significant contributions to the understanding of neurodevelopmental disorders, most notably in autism, attention-deficit/hyperactivity disorder, and Tourette's syndrome.|PMID:30658861; Original text:Attention-Deficit/Hyperactivity Disorder (Attention-Deficit/Hyperactivity Disorder) and Autism Spectrum Disorder (Autism Spectrum Disorder) are both neurodevelopmental disorders originating in childhood with high associated impairments and public health significance.
autism spectrum	disease	schizophrenia	1	0	30284394	PMID:30284394; Original text:Schizophrenia and autism spectrum disorder (disorder) are significant public health problems.
fibromyalgia	disease	pain	1	0	25336035	PMID:25336035; Original text:low-dose naltrexone improved pain tolerance as shown by a significant increase on Cold pressor times for post detoxification patients from 16 seconds to 55 seconds and in fibromyalgia patients from 21 seconds to 42 seconds, and improved relatedness.
anxiety	disease	repetitive behaviors	1	0	16649827	PMID:16649827; Original text:Most studies demonstrate significant improvement in global functioning and in symptoms associated with anxiety and repetitive behaviors.
alexithymia	disease	autistic	1	0	30399531	PMID:30399531; Original text:There was also a higher prevalence of alexithymia in the disorder group (49.93% compared to 4.89%), with a significantly increased risk of alexithymia in autistic participants.
autism	disease	psychiatric disorders	1	0	21863344	PMID:21863344; Original text:Empathy, for instance, is a rather elaborated human ability, and several recent studies point to significant impairments in patients suffering from psychiatric disorders, such as schizophrenia or autism.
autism	disease	schizophrenia	2	0	21863344|19736351	PMID:21863344; Original text:Empathy, for instance, is a rather elaborated human ability, and several recent studies point to significant impairments in patients suffering from psychiatric disorders, such as schizophrenia or autism.|PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).
anxiety	disease	spectrum disorders	2	0	23357440|23357440	PMID:23357440; Original text:To examine the efficacy of a modular cognitive-behavioral therapy (a modular cognitive-behavioral therapy) protocol relative to treatment as usual (TAU) among children with high-functioning autism spectrum disorders (spectrum disorders) and clinically significant anxiety.|PMID:23357440; Original text:A total of 45 children (7-11 years of age) with high-functioning spectrum disorders and clinically significant anxiety were randomized to receive 16 sessions of weekly a modular cognitive-behavioral therapy or TAU for an equivalent duration.
inherited cancer syndrome	disease	neurofibromatosis type	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
cognitive	disease	inherited cancer syndrome	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
cognitive	disease	neurofibromatosis type	1	0	25161109	PMID:25161109; Original text:Cognitive and behavioral disorders affect nearly 80% of all children with the neurofibromatosis type 1 inherited cancer syndrome, and are among the most significant clinical manifestations for patients and their families.
autism spectrum disorders	disease	psychotic disorders	1	0	28152400	PMID:28152400; Original text:There is increasing evidence to suggest both a symptomatic overlap and a clinically significant degree of co-occurrence between Autism Spectrum Disorders (Autism Spectrum Disorders) and psychotic disorders such as schizophrenia but the nature of such relationships remain unclear.
psychotic disorders	disease	schizophrenia	1	0	28152400	PMID:28152400; Original text:There is increasing evidence to suggest both a symptomatic overlap and a clinically significant degree of co-occurrence between Autism Spectrum Disorders (Autism Spectrum Disorders) and psychotic disorders such as schizophrenia but the nature of such relationships remain unclear.
psychotic disorders	disease	symptomatic	1	0	28152400	PMID:28152400; Original text:There is increasing evidence to suggest both a symptomatic overlap and a clinically significant degree of co-occurrence between Autism Spectrum Disorders (Autism Spectrum Disorders) and psychotic disorders such as schizophrenia but the nature of such relationships remain unclear.
affective disorders	disease	multiple sclerosis	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
disorder	disease	multiple sclerosis	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
multiple sclerosis	disease	parkinson's disease	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
multiple sclerosis	disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
autism spectrum	disease	multiple sclerosis	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
ms	disease	multiple sclerosis	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
affective disorders	disease	disorder	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
affective disorders	disease	parkinson's disease	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
affective disorders	disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
affective disorders	disease	autism spectrum	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
affective disorders	disease	ms	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
disorder	disease	parkinson's disease	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
disorder	disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
autism spectrum	disease	disorder	3	0	33669008|30475454|34018333	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).|PMID:30475454; Original text:This study compared the effectiveness of a free and open-source app for teaching social and communicative behavior to children with autism spectrum disorder (disorder) to traditional picture card approaches.|PMID:34018333; Original text:Theory of mind (mind) is the ability to attribute subjective mental states to oneself and others and is significantly impaired in autism spectrum disorder (disorder).
disorder	disease	ms	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
parkinson's disease	disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
autism spectrum	disease	parkinson's disease	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
ms	disease	parkinson's disease	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
autism spectrum	disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
ms	disease	pd	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
autism spectrum	disease	ms	1	0	33669008	PMID:33669008; Original text:We found significantly altered SCFA levels in patients with autism spectrum disorder (disorder), affective disorders, multiple sclerosis (MS) and Parkinson's disease (PD).
anxiety	disease	attention deficit hyperactivity disorder	2	0	34750348|31947912	PMID:34750348; Original text:p < 0.001), attention deficit hyperactivity disorder (odds ratio = 1.42, p < 0.001), CTD (odds ratio = 1.44, p = 0.001), anxiety (odds ratio = 1.33, p < 0.001), as well as other behavioral symptoms (odds ratio = 1.45, p < 0.001) in the adjusted analysis.|PMID:31947912; Original text:A significant increase in risk was detected for autistic spectrum disorder (OR 1.53, 95% CI 1.24-1.88, p < 0.0001), attention deficit hyperactivity disorder (OR 1.39, 95% CI 1.18-1.63, p < 0.0001), depression (OR 2.17, 95% CI 2.17-11.15, p < 0.0001), anxiety (OR 6.03,
attention deficit hyperactivity disorder	disease	ctd	1	0	34750348	PMID:34750348; Original text:p < 0.001), attention deficit hyperactivity disorder (odds ratio = 1.42, p < 0.001), CTD (odds ratio = 1.44, p = 0.001), anxiety (odds ratio = 1.33, p < 0.001), as well as other behavioral symptoms (odds ratio = 1.45, p < 0.001) in the adjusted analysis.
anxiety	disease	ctd	1	0	34750348	PMID:34750348; Original text:p < 0.001), attention deficit hyperactivity disorder (odds ratio = 1.42, p < 0.001), CTD (odds ratio = 1.44, p = 0.001), anxiety (odds ratio = 1.33, p < 0.001), as well as other behavioral symptoms (odds ratio = 1.45, p < 0.001) in the adjusted analysis.
asd	disease	obesity	1	0	31595678	PMID:31595678; Original text:Children with ASD had a 41.1% greater risk (P = .018) of development of obesity.
autism spectrum disorders	disease	epilepsy	1	0	20558021	PMID:20558021; Original text:The biological and phenotypic heterogeneity of children with autism spectrum disorders (autism spectrum disorders) and epilepsy presents a significant challenge to the development of effective treatment protocols.
disorder(+spectrum disorders	disease	spectrum	1	0	26154019	PMID:26154019; Original text:The comorbid attention-deficit/hyperactivity disorder(+spectrum disorders) and spectrum disorders(+attention-deficit/hyperactivity disorder) classes were significantly less accurate (more time underestimations) compared to the Normal class (mean RTs 847 and 870 ms, respectively).
attention-deficit/hyperactivity	disease	spectrum	1	0	26154019	PMID:26154019; Original text:The comorbid attention-deficit/hyperactivity disorder(+spectrum disorders) and spectrum disorders(+attention-deficit/hyperactivity disorder) classes were significantly less accurate (more time underestimations) compared to the Normal class (mean RTs 847 and 870 ms, respectively).
disorders(+attention-deficit/hyperactivity disorder	disease	spectrum	1	0	26154019	PMID:26154019; Original text:The comorbid attention-deficit/hyperactivity disorder(+spectrum disorders) and spectrum disorders(+attention-deficit/hyperactivity disorder) classes were significantly less accurate (more time underestimations) compared to the Normal class (mean RTs 847 and 870 ms, respectively).
attention-deficit/hyperactivity	disease	disorder(+spectrum disorders	1	0	26154019	PMID:26154019; Original text:The comorbid attention-deficit/hyperactivity disorder(+spectrum disorders) and spectrum disorders(+attention-deficit/hyperactivity disorder) classes were significantly less accurate (more time underestimations) compared to the Normal class (mean RTs 847 and 870 ms, respectively).
disorder(+spectrum disorders	disease	disorders(+attention-deficit/hyperactivity disorder	1	0	26154019	PMID:26154019; Original text:The comorbid attention-deficit/hyperactivity disorder(+spectrum disorders) and spectrum disorders(+attention-deficit/hyperactivity disorder) classes were significantly less accurate (more time underestimations) compared to the Normal class (mean RTs 847 and 870 ms, respectively).
attention-deficit/hyperactivity	disease	disorders(+attention-deficit/hyperactivity disorder	1	0	26154019	PMID:26154019; Original text:The comorbid attention-deficit/hyperactivity disorder(+spectrum disorders) and spectrum disorders(+attention-deficit/hyperactivity disorder) classes were significantly less accurate (more time underestimations) compared to the Normal class (mean RTs 847 and 870 ms, respectively).
anxiety	disease	generalized	1	0	21660428	"PMID:21660428; Original text:Children in both programs showed significantly lower levels of generalized anxiety and total anxiety symptoms at 6-month follow-up on SCAS-C. Clinician ratings on the CGI-S demonstrated an increase in the percentage of participants rated as ""Normal"" and ""Borderline"" for both programs."
anxiety	disease	autism spectrum disorders	2	0	23965288|19365716	PMID:23965288; Original text:Pretreatment Developmental Disability-Child Global Assessment Scale scores correlated with severity of autism spectrum disorders core symptoms (r = -.388, p = .034), pragmatic communication (r = .407, p = .032), and verbal ability (r = .449, p = .013) and did not correlate with severity of anxiety symptoms or with parent-reported adaptive behavior.|PMID:19365716; Original text:The findings indicated that each Autism Spectrum Disorders intervention group demonstrated significant gains on the WMS and significant improvement in the areas of anxiety management, joint attention, and flexibility/transitions.
autism spectrum disorders	disease	infantile spasms	1	0	25944453	PMID:25944453; Original text:Only patients with symptomatic Infantile spasms developed autism spectrum disorders (p = 0.003).
epileptic	disease	hypsarrhythmia	1	0	25944453	PMID:25944453; Original text:Other risk factors were identified such as having chronic epileptic discharges in the frontotemporal areas after disappearance of hypsarrhythmia (p = 0.005 and p = 0.007) and being of nonwhite origin (p = 0.009).
epilepsy	disease	schizophrenia	1	0	24123946	PMID:24123946; Original text:The del15q11.2 was found to be significantly associated with intellectual disability, schizophrenia, epilepsy, and disorder.
dravet syndrome	disease	intellectual disability	1	0	32334365	PMID:32334365; Original text:Many patients also have significant deficits in adaptive behavior highlighting that the majority of patients with Dravet syndrome will meet criteria for intellectual disability.
asd	disease	sleep disturbances	1	0	31437211	PMID:31437211; Original text:The prevalence of sleep disturbances in children with ASD is 40-80%, with significant effects on quality of life for the children and carers.
attention deficit hyperactivity disorder	disease	autistic spectrum disorder	2	0	30909078|31947912	PMID:30909078; Original text:More boys than girls had Attention Deficit Hyperactivity Disorder and autistic spectrum disorder, but in relative terms, the a risk ratio male/female was lower in CWE than the a risk ratio in the general population reported in other studies.|PMID:31947912; Original text:A significant increase in risk was detected for autistic spectrum disorder (OR 1.53, 95% CI 1.24-1.88, p < 0.0001), attention deficit hyperactivity disorder (OR 1.39, 95% CI 1.18-1.63, p < 0.0001), depression (OR 2.17, 95% CI 2.17-11.15, p < 0.0001), anxiety (OR 6.03,
asd	disease	attention-	1	0	20694583	PMID:20694583; Original text:Individuals with co-occurring ASD and attention-deficit/hyperactivity disorder symptoms are more severely impaired, with significant deficits seen in social processing, adaptive functioning, and executive control.
medical	disease	microcephaly	1	0	10382131	PMID:10382131; Original text:Microcephaly was significantly associated with the presence of medical disorders.
asperger's syndromed.	disease	hyperandrogenism	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
asperger's syndromed	disease	asperger's syndromed.	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
asperger's syndromed	disease	hyperandrogenism	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
autism	disease	pervasive developmental disorder	1	0	15083132	PMID:15083132; Original text:It is well tolerated without any significant side effects and is efficacious in children with autism and pervasive developmental disorder.
asd	disease	iron	1	0	29540271	PMID:29540271; Original text:However, the reciprocal comorbidity of disorder and ASD and iron levels/iron deficiency was significantly higher than in the children without these disorders.
autism spectrum disorder	disease	neurodevelopmental disorders	1	0	30658861	PMID:30658861; Original text:Attention-Deficit/Hyperactivity Disorder (Attention-Deficit/Hyperactivity Disorder) and Autism Spectrum Disorder (Autism Spectrum Disorder) are both neurodevelopmental disorders originating in childhood with high associated impairments and public health significance.
anticonvulsants	disease	seizure	1	0	23666039	PMID:23666039; Original text:On this diet, while still continuing on anticonvulsants, she showed significant improvement in seizure activity.
autism	disease	pdd	2	0	9546298|9442997	PMID:9546298; Original text:Smaller, but still statistically significant effects on symptom severity were also found, though experimental subjects still met diagnostic criteria for autism or PDD.|PMID:9442997; Original text:A significant effect of informant was found for the PDD group, and this effect was particularly pronounced when children with autism were considered separately.
autism spectrum	disease	developmental	1	0	28762296	PMID:28762296; Original text:The link between nutrition and autism spectrum disorder (disorder), which is a complex developmental disorder manifesting itself in significant delays or deviation in interaction and communication, has provided a fresh point of view and signals that nutrition may have a role in the aetiology of disorder, as well as play an active role in treatment by alleviating symptoms.
autism	disease	pervasive developmental disorders	2	0	17885895|9813776	PMID:17885895; Original text:While both instruments have good psychometric properties, the results of this study suggest that clinicians and researchers should exercise caution when utilising the the Developmental Behaviour Checklist-Autism Screening Algorithm to screen for Pervasive Developmental Disorders in individuals with significant behaviour problems, as this could decrease its diagnostic validity.|PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
autistic disorder	disease	pddnos	1	0	10097993	PMID:10097993; Original text:Only a limited number of items from the ICD-10 and DSM-IV systems for autistic disorder significantly discriminated the PDDNOS group from other disorders.
seizures	disease	tuberous sclerosis	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
pervasive developmental disorders	disease	tuberous sclerosis	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
infantile spasms	disease	tuberous sclerosis	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
mental retardation	disease	tuberous sclerosis	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
pervasive developmental disorders	disease	seizures	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
autism	disease	seizures	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
infantile spasms	disease	seizures	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
mental retardation	disease	seizures	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
infantile spasms	disease	pervasive developmental disorders	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
mental retardation	disease	pervasive developmental disorders	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
autism	disease	infantile spasms	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
infantile spasms	disease	mental retardation	1	0	9813776	PMID:9813776; Original text:Mental retardation (Mental retardation) and seizures, particularly infantile spasms, are significant risk factors in the development of autism/pervasive developmental disorders in tuberous sclerosis; however, neither are sufficient or necessary for the development of these behaviors.
autistic disorders	disease	developmental disorders	1	0	21219265	PMID:21219265; Original text:The risk was highly significant when considering the strict definition of autistic disorders as opposed to the large definition of other pervasive developmental disorders.
asds	disease	fragile x syndrome	1	0	30897358	PMID:30897358; Original text:fragile X syndrome and ASDs, while clinically and genetically distinct, share significant comorbidity, suggesting that there may be a common molecular and/or cellular basis, presumably at the synapse.
gut dysbiosis	disease	gut microbiome	1	0	31837704	PMID:31837704; Original text:More recent data, however, have shown that elevated salt consumption has a significant effect on the immune system and gut microbiome, often resulting in gut dysbiosis and induction of pro-inflammatory pathways.
pulmonary hypertension	disease	spontaneous abortion	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
preterm birth	disease	spontaneous abortion	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease	spontaneous abortion	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
low birth weight	disease	spontaneous abortion	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
autism spectrum disorders	disease	spontaneous abortion	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
preterm birth	disease	pulmonary hypertension	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease	pulmonary hypertension	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
low birth weight	disease	pulmonary hypertension	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
autism spectrum disorders	disease	pulmonary hypertension	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease	preterm birth	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
low birth weight	disease	preterm birth	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
autism spectrum disorders	disease	preterm birth	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease	low birth weight	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
attention deficit hyperactivity disorder	disease	autism spectrum disorders	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
autism spectrum disorders	disease	low birth weight	1	0	32840005	PMID:32840005; Original text:Most of the meta-analyses reported that compared to non-users, the risks of preterm birth, low birth weight, spontaneous abortion, persistent pulmonary hypertension, autism spectrum disorders, and attention deficit hyperactivity disorder in offspring of antidepressant users were significantly higher.
autism	disease	emotional and behavioral difficulties	1	0	28864836	PMID:28864836; Original text:Results showed that parents who attributed their child's autism to environmental factors, experienced emotional upset or confusion about autism, or perceived the condition to be pervasive or burdensome, were more likely to reported clinically significant emotional and behavioral difficulties.
autism	disease	emotional	1	0	28864836	PMID:28864836; Original text:Results showed that parents who attributed their child's autism to environmental factors, experienced emotional upset or confusion about autism, or perceived the condition to be pervasive or burdensome, were more likely to reported clinically significant emotional and behavioral difficulties.
emotional	disease	emotional and behavioral difficulties	1	0	28864836	PMID:28864836; Original text:Results showed that parents who attributed their child's autism to environmental factors, experienced emotional upset or confusion about autism, or perceived the condition to be pervasive or burdensome, were more likely to reported clinically significant emotional and behavioral difficulties.
gastrointestinal symptoms	disease	pervasive developmental disorder	1	0	11459079	PMID:11459079; Original text:We studied 9 Caucasian boys, 3.8-8.1 years old, with a DSM-IV diagnosis of a pervasive developmental disorder, living with their families, receiving no chronic medications, and without significant gastrointestinal symptoms.
developmentally	disease	seizure	1	0	20981762	PMID:20981762; Original text:Ideal treatment for developmentally-disabled children with epilepsy entails maximal seizure control without any significant adverse effects from the anti-epileptic drugs and good quality of life.
developmentally	disease	epileptic	1	0	20981762	PMID:20981762; Original text:Ideal treatment for developmentally-disabled children with epilepsy entails maximal seizure control without any significant adverse effects from the anti-epileptic drugs and good quality of life.
developmentally	disease	epilepsy	1	0	20981762	PMID:20981762; Original text:Ideal treatment for developmentally-disabled children with epilepsy entails maximal seizure control without any significant adverse effects from the anti-epileptic drugs and good quality of life.
epileptic	disease	seizure	1	0	20981762	PMID:20981762; Original text:Ideal treatment for developmentally-disabled children with epilepsy entails maximal seizure control without any significant adverse effects from the anti-epileptic drugs and good quality of life.
epilepsy	disease	seizure	1	0	20981762	PMID:20981762; Original text:Ideal treatment for developmentally-disabled children with epilepsy entails maximal seizure control without any significant adverse effects from the anti-epileptic drugs and good quality of life.
epilepsy	disease	epileptic	1	0	20981762	PMID:20981762; Original text:Ideal treatment for developmentally-disabled children with epilepsy entails maximal seizure control without any significant adverse effects from the anti-epileptic drugs and good quality of life.
behavioral impairments	disease	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
behavioral impairments	disease	neurofunctional impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease	behavioral impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease	behavioral impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
behavioral impairments	disease	extended selective attention	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neurofunctional impairments	disease	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
extended selective attention	disease	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease	neurofunctional impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease	neurofunctional impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
extended selective attention	disease	neurofunctional impairments	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease	autism	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease	extended selective attention	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
autism	disease	extended selective attention	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
dravet syndrome	disease	hunter syndrome	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
dravet syndrome	disease	motor delays	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
hunter syndrome	disease	motor delays	1	0	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
asd	disease	intellectual disability	1	0	28036350	PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.
developmental disorders	disease	intellectual disability	1	0	28036350	PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.
asd	disease	developmental disorders	1	0	28036350	PMID:28036350; Original text:Physician use of the 2.8MM probe-chromosomal microarray test significantly improves overall quality as well as diagnosis and treatment quality for simulated cases of pediatric Developmental disorders/ASD/intellectual disability patients, and delivers additional clinical utility over existing chromosomal microarray tests.
attention-deficit/hyperactivity disorder	disease	cerebral palsy	1	0	30446273	PMID:30446273; Original text:Assessing the occurrence of ASD and Attention-Deficit/Hyperactivity Disorder would improve the significant cost of healthcare, therapies, and overall daily living for families with children affected by Cerebral Palsy.
asd	disease	cerebral palsy	1	0	30446273	PMID:30446273; Original text:Assessing the occurrence of ASD and Attention-Deficit/Hyperactivity Disorder would improve the significant cost of healthcare, therapies, and overall daily living for families with children affected by Cerebral Palsy.
asd	disease	attention-deficit/hyperactivity disorder	1	0	30446273	PMID:30446273; Original text:Assessing the occurrence of ASD and Attention-Deficit/Hyperactivity Disorder would improve the significant cost of healthcare, therapies, and overall daily living for families with children affected by Cerebral Palsy.
asd	disease	neurodevelopmental disorders	1	0	26559825	PMID:26559825; Original text:Our results point in the direction that CNTNAP2 may not play a major role in high functioning ASD, but rather seems to have a significance in neurodevelopmental disorders or in individuals displaying intellectual delays.
intellectual delays	disease	neurodevelopmental disorders	1	0	26559825	PMID:26559825; Original text:Our results point in the direction that CNTNAP2 may not play a major role in high functioning ASD, but rather seems to have a significance in neurodevelopmental disorders or in individuals displaying intellectual delays.
asd	disease	intellectual delays	1	0	26559825	PMID:26559825; Original text:Our results point in the direction that CNTNAP2 may not play a major role in high functioning ASD, but rather seems to have a significance in neurodevelopmental disorders or in individuals displaying intellectual delays.
asperger's syndrome	disease	autistic disorders	1	0	9300193	PMID:9300193; Original text:Knowledge about the spectrum of autistic disorders, including Asperger's syndrome, has grown significantly.
major depressive disorder	disease	mdd	1	0	33130294	PMID:33130294; Original text:Two variants were significantly associated with ASD (rs9401458 and rs9401452) and one with major depressive disorder (MDD).
asd	disease	major depressive disorder	1	0	33130294	PMID:33130294; Original text:Two variants were significantly associated with ASD (rs9401458 and rs9401452) and one with major depressive disorder (MDD).
asd	disease	mdd	1	0	33130294	PMID:33130294; Original text:Two variants were significantly associated with ASD (rs9401458 and rs9401452) and one with major depressive disorder (MDD).
mental retardation	disease	schizophrenia	1	0	19736351	PMID:19736351; Original text:The collective frequency of rare copy number variations at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls (P < .001, P = .01, and P = .001, respectively, Fisher exact test).
autistic spectrum disorder	disease	developmental regression	1	0	18956241	PMID:18956241; Original text:A significant proportion of children diagnosed with Autistic Spectrum Disorder experience a developmental regression characterized by a loss of previously-acquired skills.
behavioral abnormalities	disease	psychosis	1	0	796586	PMID:796586; Original text:Childhood psychosis is a group of disorders characterized by numerous behavioral abnormalities, the most significant of which may well be in the area of language.
adhd	disease	asd	1	0	28000020	PMID:28000020; Original text:The aim of the present narrative review was to explore if structural brain imaging studies may shed light on key brain areas that are linked to both ASD and ADHD symptoms and undergo significant changes during development.
fra(x	disease	mental retardation	1	0	3052070	"PMID:3052070; Original text:We examined 31 studies which investigated the association of fra(X) syndrome with either inherited mental retardation or ""autism"" and found that the conclusion of those researchers could be significantly affected by sample size."
autism	disease	fra(x	1	0	3052070	"PMID:3052070; Original text:We examined 31 studies which investigated the association of fra(X) syndrome with either inherited mental retardation or ""autism"" and found that the conclusion of those researchers could be significantly affected by sample size."
autism	disease	neurobiological disorder	1	0	33087514	PMID:33087514; Original text:Despite the prevalence of autism and its extensive impact on our society, no U. S. Food and Drug Administration-approved treatment is available for this complex neurobiological disorder.
sleep	disease	sleep disturbance	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron deficiency	disease	sleep	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	disease	sleep	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
autism spectrum disorder	disease	sleep	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
restless	disease	sleep	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron deficiency	disease	sleep disturbance	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	disease	sleep disturbance	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
autism spectrum disorder	disease	sleep disturbance	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
restless	disease	sleep disturbance	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	disease	iron deficiency	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
autism spectrum disorder	disease	iron deficiency	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron deficiency	disease	restless	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
autism spectrum disorder	disease	iron	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
iron	disease	restless	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
autism spectrum disorder	disease	restless	1	0	17352947	PMID:17352947; Original text:Seventy-seven percent had restless sleep at baseline, which improved significantly with iron therapy, suggesting a relationship between sleep disturbance and iron deficiency in children with autism spectrum disorder.
attention	disease	behavioral difficulties	1	0	31665323	"PMID:31665323; Original text:However, children of ""overtreated"" mothers displayed significantly more attention-deficit/hyperactivity disorder symptoms and behavioral difficulties than those of normal-normal gestational thyroid function mothers."
autistic spectrum disorder	disease	depression	1	0	31947912	PMID:31947912; Original text:A significant increase in risk was detected for autistic spectrum disorder (OR 1.53, 95% CI 1.24-1.88, p < 0.0001), attention deficit hyperactivity disorder (OR 1.39, 95% CI 1.18-1.63, p < 0.0001), depression (OR 2.17, 95% CI 2.17-11.15, p < 0.0001), anxiety (OR 6.03,
attention deficit hyperactivity disorder	disease	depression	1	0	31947912	PMID:31947912; Original text:A significant increase in risk was detected for autistic spectrum disorder (OR 1.53, 95% CI 1.24-1.88, p < 0.0001), attention deficit hyperactivity disorder (OR 1.39, 95% CI 1.18-1.63, p < 0.0001), depression (OR 2.17, 95% CI 2.17-11.15, p < 0.0001), anxiety (OR 6.03,
anxiety	disease	autistic spectrum disorder	1	0	31947912	PMID:31947912; Original text:A significant increase in risk was detected for autistic spectrum disorder (OR 1.53, 95% CI 1.24-1.88, p < 0.0001), attention deficit hyperactivity disorder (OR 1.39, 95% CI 1.18-1.63, p < 0.0001), depression (OR 2.17, 95% CI 2.17-11.15, p < 0.0001), anxiety (OR 6.03,
intellectual	disease	intellectual disability	1	0	24246273	PMID:24246273; Original text:Although there are numerous quality of life instruments in the, field of intellectual disability, most of them are addressed to those, people with the highest levels of functioning, while only a few are, suitable for people with the lowest levels (i.e., people with profound, and severe intellectual disabilities, or people with intellectual and, developmental disabilities and other significant medical conditions or, disabilities).
overweight	disease	underweight	2	0	30470952|30470952	PMID:30470952; Original text:For maternal parental body mass index (13 studies), both maternal obesity [OR 1.41 (95% CI 1.19-1.67)] and maternal overweight [OR 1.16 (95% CI 1.05-1.27)] were significantly associated with disorder, while maternal underweight was not associated with disorder [OR 1.08 (95% CI 0.98-1.20)].|PMID:30470952; Original text:Relative to normal weight, maternal obesity and overweight were significantly associated with increased disorder risk, while maternal underweight was not associated with disorder.
obesity	disease	overweight	2	0	30470952|30470952	PMID:30470952; Original text:For maternal parental body mass index (13 studies), both maternal obesity [OR 1.41 (95% CI 1.19-1.67)] and maternal overweight [OR 1.16 (95% CI 1.05-1.27)] were significantly associated with disorder, while maternal underweight was not associated with disorder [OR 1.08 (95% CI 0.98-1.20)].|PMID:30470952; Original text:Relative to normal weight, maternal obesity and overweight were significantly associated with increased disorder risk, while maternal underweight was not associated with disorder.
obesity	disease	underweight	2	0	30470952|30470952	PMID:30470952; Original text:For maternal parental body mass index (13 studies), both maternal obesity [OR 1.41 (95% CI 1.19-1.67)] and maternal overweight [OR 1.16 (95% CI 1.05-1.27)] were significantly associated with disorder, while maternal underweight was not associated with disorder [OR 1.08 (95% CI 0.98-1.20)].|PMID:30470952; Original text:Relative to normal weight, maternal obesity and overweight were significantly associated with increased disorder risk, while maternal underweight was not associated with disorder.
asperger syndrome	disease	brain abnormalities	1	0	12585818	PMID:12585818; Original text:No consistent focal brain abnormalities for Asperger Syndrome were detected.
alzheimer disease	disease	autism	1	0	21482951	PMID:21482951; Original text:The relatively lower sAβ precursor proteinα level in Alzheimer disease may contribute to Alzheimer disease symptoms that significantly contrast with those of fragile X syndrome and autism.
autism	disease	fragile x syndrome	1	0	21482951	PMID:21482951; Original text:The relatively lower sAβ precursor proteinα level in Alzheimer disease may contribute to Alzheimer disease symptoms that significantly contrast with those of fragile X syndrome and autism.
alzheimer disease	disease	fragile x syndrome	1	0	21482951	PMID:21482951; Original text:The relatively lower sAβ precursor proteinα level in Alzheimer disease may contribute to Alzheimer disease symptoms that significantly contrast with those of fragile X syndrome and autism.
autistic	disease	intellectual disability	1	0	18565495	PMID:18565495; Original text:There was a strong discrepancy in relative risk (relative risk) according to IQ, with more autistic patients with intellectual disability having epilepsy (relative risk = .555; 95% confidence interval [CI]: .42-.73; p < .001).
autism	disease	impairment in socialization and communication	1	0	22999292	PMID:22999292; Original text:Autism is a neurodevelopmental disorder that causes significant impairment in socialization and communication.
autism	disease	neurodevelopmental disorder	1	0	22999292	PMID:22999292; Original text:Autism is a neurodevelopmental disorder that causes significant impairment in socialization and communication.
impairment in socialization and communication	disease	neurodevelopmental disorder	1	0	22999292	PMID:22999292; Original text:Autism is a neurodevelopmental disorder that causes significant impairment in socialization and communication.
autism	disease	developmental delay	1	0	21851192	PMID:21851192; Original text:Recently published data from our lab observed that children with autism spent significantly less time in this state during a single night recording than did typically developing children and those with developmental delay without autism.
autism spectrum disorder	disease	behavioral and neuropsychiatric symptoms	1	0	28303420	PMID:28303420; Original text:In a retrospective, naturalistic review of 74 individuals aged 30 and older meeting DSM-5 criteria for Autism Spectrum Disorder, the point prevalence of behavioral and neuropsychiatric symptoms (behavioral and neuropsychiatric symptoms) declined significantly for 12 of 13 behavioral and neuropsychiatric symptoms over a mean of 25 years while many other features of Autism Spectrum Disorder remained stable.
autism spectrum disorders	disease	fragile x syndrome	1	0	33170170	PMID:33170170; Original text:We selected 174 genes (64 X-linked and 110 autosomal) for an NGS panel in order to screen patients with Intellectual disability and/or autism spectrum disorders, after fragile X syndrome and significant Copy Number Variants have been excluded.
fragile x syndrome	disease	intellectual disability	1	0	33170170	PMID:33170170; Original text:We selected 174 genes (64 X-linked and 110 autosomal) for an NGS panel in order to screen patients with Intellectual disability and/or autism spectrum disorders, after fragile X syndrome and significant Copy Number Variants have been excluded.
autism spectrum disorders	disease	intellectual disability	1	0	33170170	PMID:33170170; Original text:We selected 174 genes (64 X-linked and 110 autosomal) for an NGS panel in order to screen patients with Intellectual disability and/or autism spectrum disorders, after fragile X syndrome and significant Copy Number Variants have been excluded.
